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Resumo 
Glutamato é o principal neurotransmissor excitatório no cérebro, sendo bastante importante 
em várias funções do sistema nervoso central. Alterações no sistema glutamatérgico estão 
envolvidas em doenças como esquizofrenia e ansiedade. Tem vindo a ser demonstrado que a 
activação de receptores mGlu2 reduz a transmissão glutamatérgica nas regiões cerebrais associadas 
a estas doenças. Por esta mesma razão, a activação destes receptores tem sido alvo de investigação 
para desenvolvimento de novas técnicas terapêuticas, especialmente com o uso de modeladores 
alostericos positivos (PAMs); estes modeladores ligam-se a uma zona do receptor diferente do local 
de ligação do glutamato.  
Dado que a área de estudo dos PAM do receptor mGlu2 se encontra em expansão e o 
primeiro ensaio clínico está a decorrer é bastante importante obter mais informacão sobre o 
correcto local de ligacão destes ligandos. Esta informacão também pode suportar e facilitar os 
esforços da investigação química. Com o objectivo de identificar os aminoácidos responsáveis pela 
interação entre os PAMs e  o receptor mGlu2, foi efectuada modulação molecular e docking de PAMs 
de receptores mGlu2 em paralelo com mutagénese dirigida. Nos receptores mGlu2 mutantes foi 
avaliado o impacto das mutações na actividade e afinidade dos PAMs. Este estudo confima a 
importância de aminoácidos previamente demonstrados como importantes na actividade de PAMs 
estruturalmente diferentes nestes receptores. É tambem demonstrado que adicionais aminoácidos 
seleccionados com base na comparação de sequencias entre mGlu2/3 parecem não ser importantes 
na actividade dos PAMs. A informação obtida neste estudo tambem demonstra que a actividade dos 
modeladores testados é reduzida devido à diminuição da afinidade de ligação. Toda esta informação 
oferece um melhor entendimento sobre o ‘binding pocket’ para PAMs do receptor mGlu2.  
 
Palavras-chave: receptor mGlu2, local de ligação alostérico, modulador alostérico positivo, 
mutagénese 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract  
Glutamate is the major excitatory neurotransmitter in the brain and plays an important role 
in a wide variety of central nervous system functions. Alterations in the glutamatergic system are 
involved in disorders like schizophrenia and anxiety. It has been shown that activation of the 
metabotropic glutamate 2 receptor reduces the glutamatergic transmission in brain regions 
associated with these disorders. Therefore, activation of mGlu2 receptor is being pursued as a novel 
therapeutic approach, specially using positive allosteric modulators (PAMs), which bind to a site 
other than that of the endogenous mGlu2 receptor agonist glutamate.  
Since the field of mGlu2 PAMs is expanding and the first clinical studies are ongoing with 
mGlu2 PAMs, it will be important to get more insight into the actual binding site of these ligands.  
This knowledge may also facilitate and support future chemistry endeavors.  In order to  identify the 
amino acids important for the activity of mGlu2 PAMs, homology modeling and docking of mGlu2 
receptor PAMs were performed in parallel with site-directed mutagenesis. Mutant mGlu2 receptors 
were generated and the impact of these mutations on activity and affinity of PAMs was evaluated. 
This study confirms the importance of several amino acids previously shown as crucial for the activity 
of structurally diverse mGlu2 receptor PAMs.  It furthermore demonstrates that additional amino 
acids that were selected based on mGlu2/3 comparison did not seem to be important for PAM 
activity. Our data also suggest that their activity is reduced due to lower binding affinity. All this 
sheds further light on the mGlu2 PAM binding pocket. 
 
Keywords: mGlu2 receptor, allosteric binding site, positive allosteric modulator, mutagenesis 
 
 
 
 
 
 
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Introduction
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1.1. G Protein-Coupled Receptors 
The majority of transmembrane signal transduction responses to hormones and 
neurotransmitters is mediated by G protein-coupled receptors (GPCRs) (Gether & B. K. Kobilka 1998). 
GPCRs are the largest class of cell-surface receptors (Schwalbe, H. and Wess 2002), being extensively 
expressed in the body and playing an important role in virtually every organ system. These receptors 
have also been implicated in a multitude of human disorders and numerous diseases have been 
linked to mutations and polymorphisms in GPCRs (P Jeffrey Conn et al. 2009). It has been estimated 
that over than 800 genes encode for a GPCR. Of those, almost half are likely to encode sensory 
receptors, leaving about 400 receptors that are potentially druggable, of which around 30 are targets 
of currently marketed drugs (Caterina Bissantz et al. 2004; Wise et al. 2002). 
For approximately 210 receptors, the natural ligand has been identified, leaving around 160 
orphan receptors with no known ligand or function (Wise et al. 2002). 
Though all GPCRs have a common structural architecture, they display multiple orthosteric 
binding modes due to the substantial diversity of endogenous ligands that they recognize (Gether & 
B. K. Kobilka 1998).  
1.1.1. GPCR structure 
GPCRs are composed of a single peptide, between 400-500 amino acids, however the length 
can go up until 1200 amino acids.  Sequence comparison between the different GPCRs revealed the 
existence of different families sharing no sequence similarity (Bockaert, J; Pin 1999). In general, these 
receptors have in common a central core domain composed of seven transmembrane-spanning α 
helices (TM domains) connected by alternating 3 intracellular (IL1-IL3) and 3 extracellular (EL1-EL3) 
loops, with the amino terminus located on the extracellular side and the carboxy terminus on the 
intracellular side  (Gether 2000; Vauquelin & von Mentzer 2007). GPCRs differ in the length and 
function of their N-terminal extracellular domain, their C-terminal intracellular domain and their 
intracellular loops, providing specific properties (Figure 1)  (Bockaert, J; Pin 1999).  
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1.1.2. GPCR mode of action  
GPCRs become active when coupled to G proteins. In a resting state, G proteins form a 
heterotrimer, consisting of a guanine nucleotide binding α subunit (38-52 KDa), a β subunit (35 KDa) 
and a γ subunit (8-10 KDa). The α subunits are hydrophilic and are largely involved in the recognition 
of “effector components”, being anchored to the plasma membrane due to their coupling to the β-γ 
complexes. The β and γ subunit are always closely associated and the complex formed by these two 
subunits is presumed to be interchangeable from one G protein to another (Vauquelin & Von 
Mentzer 2007). 
The specificity of GPCR signaling relies on the existence of closely related molecular species 
of the G protein subunits. Based on the sequence of the α subunits, G proteins have been grouped 
into four families; at least 6 and 12 different β and у subunits have been described, respectively (see 
Table 1) ( Hermans 2003; Vauquelin and Von Mentzer 2007). 
Receptor activation, upon agonist binding, leads to an exchange of a molecule of GDP by a 
molecule of GTP occurs within the active site of the α-subunit. After the binding of GTP, the 
heterotrimeric complex is dissociated and the different subunits are able to interact with intracellular 
or membrane effectors. (Gether & B. K. Kobilka 1998)  
The intrinsic GTPase activity of the αsubunit hydrolyses GTP into GDP, restoring its initial 
inactive conformation (Hermans 2003). Receptor inactivation or desensitization can also be mediated 
by protein kinase A (PKA) or C (PKC), or by G protein-coupled kinases (GRKs). It is important to note 
that arrestin can also prevent the interaction between GPCRs and G protein (Lundstrom & Chiu 
2006).   
 GPCRs can interact with other proteins rather than G proteins. The interaction of tyrosine 
kinase with the receptor result in activation of the extracellular signal-regulated kinase 
(ERK)/mitogen-activated protein kinase (MAPK) cascade. Furthermore, interaction between β-
arrestin and c-Src facilitate GPCR-dependent activation of the ERK/MAPK pathway (Lundstrom & Chiu 
2006).   
Figure 1. Structural differences between the different GPCRs families [Image adapted from (Gether 2000)] 
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The complexity of intracellular response is a consequence of the diversity in the signal 
handling at multiple levels of the response process. It can be due to receptor subtypes that show 
distinct G protein coupling specificities (Figure 2A). Another level of signaling diversity is related to 
the ability of a single G protein subtype to elicit the activation of a variety of intracellular cascades 
(Figure 2B). Moreover, the divergence in cell signaling may result from secondary modulation of 
intracellular effectors (Figure 2C). Additionally, a further complexity in cell signaling can be related to 
the possible or successive coupling of a given receptor with distinct G proteins (Figure 2D)(Hermans 
2003). 
 
 
Figure 2. Intracellular signaling divergence in response to a single transmitter. (A) Transmitter binds to different receptor 
subtypes, showing distinct G protein coupling specificities. (B) Transmitter binds to a single receptor and triggers the direct 
activation of distinct intracellular effectors through a single G protein. (C) Transmitter binds to a single receptor that shows 
selectivity for a single intracellular effector through a single G protein, but divergence occurs at downstream levels in the 
signaling cascade. (D) Transmitter binds to a single receptor that mediates distinct signaling through direct interaction with 
multiple G proteins [image taken from (Hermans 2003)]. 
 
 
 
 
 
 
 
 
 
 
 
19 
 
 Table 1. G protein subunits and their primary effector [Adapted from (Hermans 2003; Vauquelin & von Mentzer 2007)] 
Subunit Family Main subtypes Primary effector 
α 
αs Gαs, Gαolf Adenylate cyclase ↑ 
αi/o Gαi1-3, GαoA-B, Gαt1-2, GαZ 
Adenylate cyclase ↑, K
+
 
channels↑, Ca
2+ 
channels↓, 
Cyclic GMP, 
Phosphodiesterase↑ 
αq/11 Gαq, Gα11, Gα14-16 Phospholipase C ↓ 
α12/13 Gα12-13 ? 
β β1-5 (6) 
Different assemblies of 
β/у subunits 
Adenylyl cyclase ↑↓, 
Phospholipases ↑, 
Phosphatidylinositol 3-
kinase ↑ 
У У1-11 (12?)  
Protein Kinase C and D ↑, 
GPCR kinases ↑, Ca
2+
, K
+
 
(and Na
+
) channels 
 
1.1.3. Families of GPCRs 
GPCRs have been divided into diverse families, sharing around 20% of sequence identity in 
their TM domains. There are 3 major families: Family A, also called class I, is the rhodopsin-like 
receptor family with ligands such as neuropeptides, chemokines and prostaniods (Figure 1); family B 
(class II) is also called the secretin/glucagon/VIP family;  family C or class III are metabotropic 
glutamate receptor-like (Vauquelin & Von Mentzer 2007). 
  
1.1.3.1. Family A 
Family A GPCRs is the largest and most studied family. Receptors of this family can be divided 
into six subgroups (Gether 2000). In almost all of these receptors, a disulfide bridge connects the 
second and third extracellular loop. Moreover, they possess a palmitoylated cysteine in the carboxy-
terminal tail causing formation of a putative fourth intracellular loop. The homology between all 
family A receptors is low and restricted to highly conserved key residues, which suggests an essential 
role for the structural and/or functional integrity of the receptors (Gether 2000; Vauquelin & Von 
Mentzer 2007).  The only residue that is conserved among all family A is the arginine in the Asp-Arg-
Tyr (DRY) motif at the cytoplasmatic side of transmembrane segment 3  (Gether 2000).  This motif is 
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not present in the others GPCRs families and has been subject of much work attempting to 
understand the mechanisms of receptor activation and interaction with G-proteins (Flanagan 2005). 
Presumably mediates interactions with both G proteins and arrestins and serves to maintain the 
receptor transmembranes in an inactive conformation in the absence of ligand (Marion et al. 2006) . 
In general, endogenous ligands of this family bind to the 7TM (Vauquelin & Von Mentzer 2007), 
which is interesting since, as it will be discuss later, for family C this is the allosteric binding site.  
 
1.1.3.2. Family B 
This family includes about 65 members and represents an ancient signaling system that 
appears to play an important role in many biological processes. For that, they represent an 
interesting pharmaceutical target. If we look to their sequence, these GPCRs can be divided into 
three subfamilies (Vauquelin & Von Mentzer 2007). Despite of having the disulfide bridge connecting 
the EL2 and EL3, this family does not contain any of the structural features that characterize family A. 
The major characteristic of these receptors is the presence of a large extracellular amino terminus 
containing several cysteines, probably forming a network of disulfide bridges (Gether 2000).  
 
1.1.3.3. Family C 
Family C includes the receptors for the main neurotransmitters (glutamate and GABA), for 
Ca2+, for sweet and amino acid taste compounds, for some pheromone molecules and odorants in 
fish. Of all genes enconding for GPCRs, 22 encode just for this class (Rondard et al. 2011).  The 
metabotropic receptors for glutamate are the focus of this thesis. 
The Family C GPCR family presents a long amino terminus (500-600 aa), where the othosteric 
binding site can be found and displays remote sequence homology with bacterial periplasmatic 
binding proteins (PBPs), specially with the leucine/isoleucine/valine binding protein (Gether 2000) .  
Like the other families, Family C has  putative disulfide-forming cysteines, but do not share 
any conserved residues with the other families (Vauquelin & Von Mentzer 2007).  
The C-terminus is important for modulating G protein coupling and is also a target for 
alternative splicing, regulation by phosphorylation and modulatory protein-protein interactions 
(Niswender & P Jeffrey Conn 2010). 
 
1.1.3.4. Family D, E and F 
Yeast pheromone receptors make up two minor unrelated subfamilies, Family D also called 
STE2 receptors and Family B (STE3 receptors). In the amoeba Dictyostelium Discoideum four different 
cAMP receptors constitute another minor subfamily – Family F (Gether 2000). 
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1.2. Glutamatergic system 
Glutamate is the primary excitatory neurotransmitter in the brain. This neurotransmitter 
accounts for 100% of pyramidal neurons, virtually all cortico-cortical neurotransmission and 
approximately 60% of total brain neurons (Kantrowitz & Javitt 2010). 
Glutamate plays key roles in physiological processes including learning and memory and 
central pain transduction mechanisms. These processes are mediated by diverse families of receptors 
and transporters (C. J. Swanson et al. 2005; Kantrowitz & Javitt 2010). 
Glutamate transporters are divided in plasma membrane glutamate transporters (excitatory 
amino acid transporters - EAAT) and  vesicular glutamate transporters (vGluT1 and vGluT2) (C. J. 
Swanson et al. 2005).  Vesicular glutamate transporters are important to transport glutamate into 
synaptic vesicles after its production. Glutamate is stored in synaptic vesicles at high concentrations, 
and protected from degradation before being released in a Ca2+ dependent manner into the synaptic 
cleft by exocytosis (Sanacora et al. 2008). 
Glutamate is also involved  in pathological processes such as excitotoxic neuronal injury 
which follows central nervous system (CNS) trauma or ischemia (Hudspith 1997). Therefore, a tight 
control of glutamatergic neurotransmission is required in order to maintain optimal neuronal 
function and prevent overactivation of the system. For that, multiple levels of regulatory processes 
have evolved to ensure that glutamatergic excitation is maintained within narrow boundaries. These 
regulatory processes are important because abnormal function of the glutamatergic system has been 
implicated in the pathophysiology of many different disorders including amyotrophic lateral sclerosis 
(ALS), Huntington’s chorea, epilepsy, Alzheimer’s disease, schizophrenia, and anxiety disorders. Thus, 
dysfunction of glutamatergic neurotransmission may be a common pathophysiological mechanism, 
aspects of which are shared between several disorders (Sanacora et al. 2008).   
Hence, pharmacological manipulation of glutamate receptors is likely to be beneficial in 
important and common diseases of the nervous system (Tsai & Coyle 2002; Sanacora et al. 2008).  
 
1.2.1. Glutamate receptors 
There are two major categories of glutamate receptors (Figure 3): the ionotropic glutamate 
(iGlu) receptors which are ligand-gated ion channel receptors that modulate synaptic excitability and 
plasticity and the metabotropic glutamate (mGlu) receptors, which regulate glutamate release and 
modify postsynaptic excitability to glutamate (C. J. Swanson et al. 2005).  
For a visual on the distribution of the transporters and receptors see Figure 4. 
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Figure 3. Molecular families of glutamate receptors (Siegel et al. 2006) 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Hypothetical synapse illustrating the general synaptic localization and function of glutamatergic receptors and 
transporters (C. J. Swanson et al. 2005) 
 
1.2.1.1. Ionotropic glutamate receptors  
In the case of iGlu receptors, the agonist binding sites and associated ion channel are 
incorporated into the same macromolar complex. Agonist binding leads to a conformational change 
in the receptors that increases the probability of channel opening. There are three classes of iGlu 
receptors: N-methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid 
(AMPA) and kainate (KA) receptors, in accordance with differential sensitivity to these synthetic 
glutamate analogs. It is important to note that the affinity for glutamate is different for the different 
glutamate receptors (Siegel et al. 2006). 
AMPA receptors mediate fast, rapidly desensitizing excitation at most synapses, and are 
responsible for the initial reaction to glutamate in the synapse. Their activation opens the pore which 
results in the inward flow of sodium, leading to the depolarization of the neuronal membrane. These 
receptors comprise a homo or heteromeric complex of four subunits (GluR1-4) and are functionally 
diverse since they have differences in individual subunit expression, posttranscriptional 
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modifications, and alternative splicing modifications. At mature synapses, AMPA receptors are 
usually co-expressed with NMDA receptors (Siegel et al. 2006). 
NMDA receptors are believed to exist primarily as tetrameric complexes that have two 
obligatory NR1 subunits and two NR2 subunits. There are at least eight splice variants of the NR1 
subunit, four NR2 genes (NR2 A-D), and two NR3 subunits (NR3A and NR3B) (Sanacora et al. 2008). 
The binding sites of these receptors consist of recognition sites for two different agonists (glutamate 
and glycine) and a polyamine regulatory site, all of which promote receptor activation (Siegel et al. 
2006). The binding site for glutamate has been found in the NR2 subunit and the site for the co-
agonist glycine has been localized to the NR1 subunit (Sanacora et al. 2008).   Also, there are 
separate recognition sites for Mg2+, Zn2+ and H+  (Siegel et al. 2006).  NMDA receptors are normally 
blocked under resting conditions by the obstructing effects of Mg2+ ; membrane depolarization and 
the combined binding of two molecules of glutamate and two molecules of glycine or D-serine is 
needed for NMDA receptor activation (Sanacora et al. 2008). Thus, NMDA receptor activation serves 
as a functional marker of converging excitatory input and produces excitation over longer periods of 
time (Sanacora et al. 2008). 
The other type of iGlu receptors, KA receptors, are coded by two gene families coding for the 
low affinity GluR5-7 subunits and the high affinity KA1 and KA2 subunits. KA receptors are associated 
with voltage-dependent channels, like AMPA receptors, that allow the influx of Na+ ions that mediate 
fast excitatory neurotransmission; however they appear to have a distinct distribution, when 
compared to AMPA receptors (Sanacora et al. 2008). 
1.2.1.2. Metabotropic glutamate (mGlu) receptors 
The discovery of mGlu receptors dramatically altered the traditional view of glutamatergic 
neurotransmission since activation of mGlu receptors can modulate activity in glutamatergic circuits 
which previously was associated with other neuromodulators like dopamine, serotonine, 
acetylcholine and norepinephrine (P J Conn & J. P. Pin 1997). 
It is known that mGlu receptor-mediated glutamate activity influences Ca2+ and K+ ion 
channels, NMDA and AMPA receptor currents, glutamate and GABA release (P J Conn & J. P. Pin 
1997).  One of the most prominent physiologic effects of this type of receptors is reduction of 
transmission at glutamatergic synapses. This effect is typically mediated by presynaptic mGlu 
receptors that serve as autoreceptors to reduce glutamate release (P J Conn & J. P. Pin 1997). 
Since iGlu receptors are expressed by almost every type of neurons and mediate fast 
excitatory neurotransmission, direct pharmacological manipulation of these receptors is not a good 
idea because inhibition could produce disruption of brain function. Therefore, mGlu receptors that 
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activate intracellular signaling cascades offer an opportunity for developing drugs that regulate 
glutamate neurotransmission (B. A. Rowe et al. 2008). 
 
1.2.2. mGlu receptor family 
The mGlu receptor family is divided into three major groups according to their amino acid 
sequence homology, pharmacology and the preferred signal transduction mechanisms they couple to 
when expressed in vitro (C. J. Swanson et al. 2005). Group I mGlu receptors (mGlu1 and mGlu5) are 
located primarily postsynaptically where they couple to Gαq/G11. Activation of group I results in 
phospholipase C (PLC) stimulation, an increase in phosphoinositides hydrolysis and increases in 
intracellular calcium (Vinson & P Jeffrey Conn 2012). Group II (mGlu2 and mGlu3) and group III (mGlu4 
and mGlu 6-8) receptors are coupled to Gαi/Gαo (Vinson & P Jeffrey Conn 2012) and typically inhibit 
adenylyl cyclase activity when expressed in vitro (C. J. Swanson et al. 2005) and modulate voltage-
dependent ion channels. Despite the same mode of action, the distribution of these two groups of 
receptors (group II and III) is different. While group II mGlu receptors are localized mainly 
presynaptically and are primarily distributed in forebrain regions (this topic will be discuss later), 
group III mGlu receptors are expressed both presynaptically and postsynaptically. The distribution of 
this group is more restricted, some of the members of this group are expressed in the cerebellum 
and striatum and other members are present in the hippocampus.  (Vinson & P Jeffrey Conn 2012). 
A variety of in vitro and in vivo studies  suggest that specific mGlu receptors subtypes play 
neuromodulatory roles in different central nervous system circuits and that specific subtypes may 
provide targets for novel treatment strategies for neurological and psychiatric disorders, including 
anxiety (C. J. Swanson et al. 2005) , pain (Fisher et al. 2002), schizophrenia (P Jeffrey Conn et al. 2008) 
and cognitive disorders (Campbell et al. 2004).  
In the case of group II, their activation leads to a reduction in transmission at glutamatergic 
synapses in brain regions where excessive glutamatergic neurotransmission may be implicated in 
anxiety and schizophrenia, principally, in the prefrontal cortex and hippocampus. Hence, activation 
of these receptors may provide anxiolytic and/or antipsychotic effects (P Jeffrey Conn et al. 2008; C. 
J. Swanson et al. 2005).  
 
1.2.2.1. Structure 
mGlu receptors as the other GPCRs are divided in three major domains, as mentioned in 
section 1.1.1 (Figure 5). These receptors, in the particular, have an extracellular N-terminal domain 
exceptionally large and is linked to the 7TM domain by an amino acid stretch rich in cysteine residues 
(Urwyler 2011). 
The extracellular ligand recognition N-terminal domain has a so-called bi-lobed structure 
(Venus flytrap domain; VFD) that can adopt an open or closed configuration in the absence or 
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presence of an agonist, respectively (P J Conn & J. P. Pin 1997; F Gasparini & Spooren 2007; Bessis et 
al. 2000).  This change, caused by glutamate binding at the VFD is transmitted via the cysteine-rich 
domain (CRD).  
The N-terminal recognition site is a well conserved site probably because it has to 
accommodate the natural ligand glutamate (Urwyler 2011). 
 
 
The identification of the glutamate binding site or orthosteric site in the N-terminal 
extracellular domain of mGlu receptors was possible by X-ray crystallography, ligand binding studies 
and mutagenesis (Kunishima et al. 2000), which will be discussed further in another section.  
 
 
 
 
 
 
 
 
 
 
 
Figure  5. Schematic illustration of the mGlu  receptor structure (P Jeffrey Conn et al. 2008) 
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Table 2. Classification of the metabotropic glutamate (mGlu) receptors (C. J. Swanson et al. 2005) 
Family 
receptor 
Coupling Key localization and actions 
Group/subtype-
selective 
pharmacological 
agents 
Group I 
mGlu1 
Excitatory 
Gq-coupled 
Most often postsynaptic at glutamatergic synapses. Involved in 
synaptic plasticity, including long-term potentiation/depression. 
Cerebellar localization in granular cell and parallel fibre layers 
Agonists: DHPG, 1S,3R-
ACPD, quisqualate 
Antagonist: LY393675 
Inverse agonist (or 
allosteric antagonist): 
LY367385 
mGlu3 
Excitatory 
Gq-coupled 
Most often postsynaptic at glutamatergic synapses, also found in 
glial cells. High expression in several forebrain regions including 
hippocampus and amygdala. Involved in synaptic plasticity specially 
long-term potentiation 
Agonists: DHPG, 1S,3R-
ACPD, quisqualate, 
CHPG 
Inverse agonist (or 
allosteric antagonist): 
MPEP 
Group II 
mGlu2 
Inhibitory 
Gi/Go 
coupled 
Localization largely presynaptic on glutamatergic and other 
neurotransmitter synapses. High expression in forebrain regions 
including hippocampus and amygdala, can also be find in certain 
layers with the cortex and cerebellum. Linked to hippocampal LTD 
and regulation on medial perforant path 
Agonists: DCG-IV, 
2R,4R-APDC, 1S,3R-
ACPD, LY354740, 
LY379268 
Antagonist: LY341495 
Potentiator: 4-MPPTS 
(LY487379), 4-APPES, 
CBiPES 
mGlu3 
Inhibitory 
Gi/Go 
coupled 
Widely expressed in glial cells but also discrete localization both pre 
and postsynaptic on glutamatergic and other neurotransmitter 
synapses. Expression within forebrain regions including 
hippocampus and thalamus. Linked to neurotropin release from 
glial cells 
Agonists: DCG-IV, 
2R,4R-APDC, 1S,3R-
ACPD, LY354740, 
LY379268 
Antagonist: LY341495 
 
Group III 
mGlu4 
Inhibitory 
Gi/Go 
coupled 
Localization both pre and postsynaptic on glutamatergic and other 
neurotransmitter synapses. Presynaptic in cerebellar fibres and 
linked to cerebellar plasticity and motor learning 
Agonist: L-SOP, ACPT-
a, L-AP4 
Antagonists: MSOP, 
MAP4, CPPG 
mGlu6 
Inhibitory 
Gi/Go 
coupled 
Expression confirmed only in retinal bipolar ON cells. Knockout 
animals reported to have visual acute deficits 
Agonists: L-SOP, L-AP4 
Glutamate-site 
antagonist: MSOP, 
MAP4 
mGlu7 
Inhibitory 
Gi/Go 
coupled 
Localization both pre and postsynaptic on glutamatergic and other 
neurotransmitter synapses in limbic and cortical regions. Has lower 
affinity for glutamate than other mGlu subtypes and only 
presynaptic inhibitory mGlu localized to active zone of synapses. 
Thought to serve a classical autoreceptor function 
 
Agonists: L-SOP, L-AP4 
Antagonists: MSOP, 
MAP4, LY341495 (100-
fold lower affinity than 
group II) 
mGlu8 
Inhibitory 
Gi/Go 
coupled 
Localization largely presynaptic on glutamatergic and other 
neurotransmitter synapses. High expression un forebrain regions 
including hippocampus and amygdala. Linked to regulation of 
lateral perforant path 
Agonists: L-SOP, L-AP4, 
3,4-DCPG 
Antagonists: MSOP, 
MAP4 
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1.3. Glutamate and diseases  
1.3.1. Schizophrenia 
Schizophrenia is a devasting psychiatric illness that has a prevalence of approximately 0.8% 
of the population and a lifetime prevalence of approximately 1% (Lodge & A. a Grace 2011; P Jeffrey 
Conn et al. 2008; Siegel et al. 2006; Stilo & Murray 2010). Although causes of schizophrenia remain 
unknown, the disease has been extensively characterized from both a symptomatic and 
neurocognitive perspective, and much information has accumulated about elements such as genetic 
causation and longitudinal course (Javitt 2010).  
Even though this disease was once seen as a disorder that affects only a few brain regions 
and regionally discrete neurotransmitter systems such as dopamine, more recent findings implicate 
widespread cortical and subcortical dysfunction, suggesting a more generalized etiology (Javitt 2010). 
 
1.3.1.1. Clinical aspects 
Schizophrenia is characterized by three partially independent symptom clusters. These 
symptoms are designated as positive symptoms that include hallucinations, delusions, thought 
disorder, paranoia, in general reflect features of the schizophrenia experience that are not shared by 
the general population; negative symptoms like social withdrawal, anhedonia, apathy, paucity of 
speech, basically features of normal experience that are reduced in individuals with schizophrenia. 
The other group of symptoms is cognitive impairments. Cognitive deficits are typically associated 
with deficits in perception, attention, learning, short- and long-term memory and executive function 
(P Jeffrey Conn et al. 2008; Javitt et al. 2001; Lodge & A. a Grace 2011; Siegel et al. 2006). The 
cognitive impairment in this  disease is one of the major disabilities associated with the illness and is 
considered a reliable predictor of long-term disability and treatment outcome (P Jeffrey Conn et al. 
2008). 
 
1.3.1.2. Neurotransmitter hypothesis 
 
Dopamine hypothesis 
For many years, the dopamine hypothesis has driven the primary line of analysis into 
schizophrenia. This hypothesis is based on a variety of observations linking dopamine dysregulation 
to the pathophysiology of the disease. This includes the finding that enhanced activity within the 
subcortical dopamine system is associated with the positive symptoms of this disorder and the fact 
that most of the antipsychotic medications are dopamine D2 receptor antagonists (A. A. Grace 2011; 
Lodge & A. a Grace 2011).  Also, there is pharmacological data showing that drugs that augment 
dopamine transmission exacerbate psychosis in schizophrenia patients and mimic it in controls (A. A. 
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Grace 2011). In other words, these drugs like amphetamines, precipitate psychotic episodes in 
normal individuals that are virtually indistinguishable from the acute psychotic episode observed in 
schizophrenia patients. Imaging studies in these patients demonstrate significantly increased release 
of dopamine in the striatum in response to amphetamine administration with the amplitude of 
increased dopamine release corresponding to the exacerbation of positive symptoms (Lodge & A. a 
Grace 2011; Vinson & P Jeffrey Conn 2012). The increased levels of dopamine were measured by a 
decrease in D2/D3 receptor binding by [
11C]raclopride and [123I]iodobenzamide with the latter study 
showing this difference specifically in patients with active symptoms of the disease. 
Regardless of these observations, there has been little direct evidence from neurochemical 
post-mortem studies to confirm an abnormality of central dopamine neuronal function in non 
treated schizophrenic patients (Rowley et al. 2001). 
 
Serotonin hypothesis 
The lesser known hypothesis in the pathophysiology of schizophrenia is hyperfunction of 5-
HT2 receptors (serotonin receptors). This hypothesis was suggested because reports have found 
changes in expression of serotoninergic receptors. Furthermore, atypical antipsychotic drugs like 
clozapine exhibit high affinity for 5-HT2  and display efficacy on negative symptoms and cognitive 
deficits despite the low affinity for D2 receptors (Rowley et al. 2001).  
Support for the 5-HT hypothesis has also been provided by the known hallucinogenic effect 
of 5-HT receptor agonists, such as lysergic acid diethylamide (LSD), mescaline and psilocin 
(Aghajanian & G.J. Marek 1999; Rowley et al. 2001). This hypothesis suggests that selective blockade 
of 5-HT2A receptors may be sufficient as a monotherapy in schizophrenia (Chavez-noriega et al. 
2005).  
 
 Glutamate hypothesis 
Beyond these hypotheses the now widely supported glutamate hypothesis of schizophrenia, 
often called the glutamate hypofunction hypothesis, is providing significant impetus in the field of 
schizophrenia research (Chavez-noriega et al. 2005). This model was based on the observation that 
phencyclidine (PCP “angel dust”), ketamine (non-competitive NDMA antagonists)  and similarly 
acting psychotomimetic compounds, like MK-801 (Vinson & P Jeffrey Conn 2012), induced their 
unique behavioral effects by blocking neurotransmission at NMDA receptors. The action of these 
compounds uniquely reproduce the symptomatic, neurocognitive and neurochemical aspects of the 
disorder which led to the concept that symptoms in schizophrenia may reflect underlying dysfunction 
or dysregulation of NMDA receptor-mediated neurotransmission (Kantrowitz & Javitt 2010; Javitt 
2010).  Furthermore, these compounds exacerbate all three types of symptoms in individuals with 
schizophrenia (Vinson & P Jeffrey Conn 2012). The involvement of glutamate receptors in 
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schizophrenia is also supported by observation, in post mortem studies, of altered glutamate 
receptor (in particular NMDA receptors) density in some brain regions, in schizophrenic patients 
(Rowley et al. 2001). 
 The NMDA receptor hypofunction hypothesis is furthermore supported by the fact that 
administration of NMDA receptor agonists improved negative symptoms and cognitive deficits in 
schizophrenia patients (Heresco-Levy 2002; Javitt et al. 2001; Tsai & Coyle 2002).  
 All these observations suggest a possible role for decreased NMDA receptor signaling in 
schizophrenia (Vinson & P Jeffrey Conn 2012) and because glutamate/NMDA receptors are located 
throughout the brain with notable density in cortical and subcortical regions, glutamatergic models 
predict widespread cortical dysfunction with particular involvement of NMDA receptors throughout 
the brain (Javitt 2010).  
This does, however, not necessarily imply a primary deficit in NMDA receptor function in the 
etiology of schizophrenia, there are a wide range of possible mechanisms by which NMDA receptor 
function could be down regulated in a manner that could contribute to the pathology. While the 
expression or functioning of the receptor itself may be compromised, NMDA receptor signal 
transduction could also be affected by changes in the level or activity of a number of proteins as well 
as any factor influencing glutamate availability at the postsynaptic site or the occurrence of 
coincident membrane depolarization (Vinson & P Jeffrey Conn 2012). 
Further, NMDA receptors are located on brain circuits that regulate dopamine release, 
suggesting that dopaminergic deficits in schizophrenia may also be secondary to underlying 
glutamatergic dysfunction (Javitt 2010). In addition, with use of imaging approaches it has been 
found that glutamatergic and dopaminergic neurotransmission seem to interplay with each other 
producing the observed symptoms (Vinson & P Jeffrey Conn 2012). 
 In resume dopaminergic models of schizophrenia account well only for positive symptoms of 
the disease. In contrast, glutamatergic models account much more fully for both negative and 
cognitive symptoms, and thus may serve as an etiological model for the syndrome as a whole (Javitt 
2010). 
 The diversity of observations has led to the hypothesis that schizophrenia is more than a 
result of a change in magnitude of neurotransmitter signaling, but is also a change in the underlying 
brain circuit (Vinson & P Jeffrey Conn 2012). 
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1.3.1.3. Glutamatergic circuitry 
Further investigation has revealed the involvement of glutamatergic pathways and signaling 
in ways that are not mutually exclusive to the hypothesized involvement of the dopaminergic system 
(Vinson & P Jeffrey Conn 2012).  
Glutamate hypofunction is relevant to the positive and cognitive symptoms observed in 
schizophrenia because NMDA receptor activation and function is a process that is critically involved 
in synaptic plasticity, a mechanism required for learning and memory formation. This process begins 
with NMDA receptor activation which requires the agonist glutamate and glycine in addition to 
membrane depolarization, resulting in calcium influx through the receptor channel (Vinson & P 
Jeffrey Conn 2012). 
NMDA receptors are located on GABAergic neurons in subcortical regions such as the nucleus 
accumbens and on glutamatergic neurons projecting from the mediodorsal thalamus to pyramidal 
neurons in the prefrontal cortex. NMDA receptors on the GABAergic neurons receive excitatory input 
from glutamatergic afferents and their activation results in an inhibitory regulation of the 
thalamocortical pathway. A reduction in NMDA receptor function on these GABAergic neurons result 
in disinhibition of thalamocortical glutamatergic signaling to the prefrontal cortex and therefore an 
increase in excitatory glutamatergic input to pyramidal neurons in the prefrontal cortex (Figure 6). 
This model is supported by the fact that psychotomimetic NMDA receptors antagonists have been 
shown to cause an increase in extracellular glutamate levels in the prefrontal cortex which has been 
hypothesized to be linked to the effects of these agents on certain aspects of cognitive function and 
locomotor activity (Vinson & P Jeffrey Conn 2012). 
 
Figure 6. Simplified schematic illustration of glutamatergic-GABAergic microcircuitry between subcortical and cortical 
regions (Vinson & P Jeffrey Conn 2012) 
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1.3.1.4. Current treatment 
Current antipsychotic treatments exert their function by blocking dopamine D2 receptors. 
There are two classes of these antipsychotics: the typical antipsychotics that include haloperidol and 
chlorpromazine and the atypical antipsychotics like olanzapine and clozapine. These two classes 
differentiate themselves in their degree of specificity for D2 over other neurochemical targets, 
occupancy time at D2 and their resulting side effect profile. Generally, the atypical group of drugs is 
less selective for, bind with lower affinity to, and has a faster off rate from the D2 receptor compared 
to the typical antipsychotics (Vinson & P Jeffrey Conn 2012).  
As said before, the currently available antipsychotic medication is only efficient at treating 
positive symptoms, in a subset of patients, but do not show a high level of efficacy towards the other 
classes of symptoms and exhibit significant side effects such as extrapyramidal symptoms (EPS) and 
tardive dyskinesia (Chavez-noriega et al. 2005). Antipsychotic treatments are not treating the 
disease, but rather produce an abnormal state that offsets the downstream dopamine dysfunction 
associated with positive symptoms (Lodge & A. a Grace 2011). Furthermore, there is a high 
prevalence of patients discontinuing treatment (reported to be >74%). Collectively, this 
demonstrates the need for improved therapies (Lodge & A. a Grace 2011).  
 The disruption in glutamatergic signaling via NMDA receptors in cortical and midbrain circuits 
in schizophrenia, (see above), has convinced investigators to follow this concept for therapeutic 
development (Vinson & P Jeffrey Conn 2012). It has been seen that agents that stimulate NMDA 
receptor-mediated neurotransmission, including glycine-site agonists and glycine transport 
inhibitors, have shown encouraging results in preclinical studies and are currently in clinical 
development (Javitt 2010; Javitt et al. 2001).  However, targeting NMDA receptor or other ionotropic 
glutamate receptors directly is not considered to be a viable approach because of their widespread 
role in fast synaptic transmission throughout the central nervous system and the potential toxicity of 
overactivation of NMDA receptors. Another option to regulate transmission through these circuits is 
to target mGlu receptors which function to modulate synaptic transmission and neuronal excitability. 
In particular, attention has been given on targeting mGlu receptor subtypes 2,3 and 5 as a novel 
treatment strategies for treatment of schizophrenia (Vinson & P Jeffrey Conn 2012).  Encouraging 
results have been observed, as well, with agents such as mGlu 2/3 receptor agonists that decrease 
resting glutamate levels, reversing potential disruption in firing patterns within prefrontal cortex and 
possibly other brain regions (Javitt 2010). 
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1.3.2. Cognition 
mGlu receptors play an important role in a number of forms of synaptic plasticity, including 
induction of hippocampal long-term potentiation (LTP), that is known to be involved in mechanisms 
of learning and memory formation. They also elicit physiologic effects in the hippocampus that might 
enhance cognitive function (P J Conn & J. P. Pin 1997).  
Since cognitive deficits are another key feature of schizophrenia and are the strongest predictor 
of long-term outcome for patients, as such, they constitute an important target for pharmacological 
treatment (Chavez-noriega et al. 2005; Green & Braff 2001).  
There is, also, some evidence suggesting that cognitive impairments form a core element of 
depression (Austin et al. 1999).  
These observations suggest that mGlu receptor ligands may be useful as cognitive enhancing 
agents in diverse disorders that cause cognitive impairments and memory deficits (P J Conn & J. P. 
Pin 1997).  Experiments in rodents and a small clinical study suggest that group II mGlu receptor 
agonists may be efficacious in ameliorating the cognitive deficits in individuals with compromised 
NMDA receptor function (Chavez-Noriega et al. 2005).  
 
1.3.3. Anxiety and Depression 
 Anxiety disorders can last at least six months and get worse if they are not treated. They 
commonly occur along with other mental illness or physical illness, including alcohol or substance 
abuse, which could mask or worsen anxiety symptoms. In some cases, the other disorders need to be 
treated before the treatment of the anxiety symptoms becomes effective (National institute of 
Health). 
In general stress- and anxiety-related illnesses represent a collection of disorders, including 
panic disorder, obsessive-compulsive disorder, post-traumatic stress disorder, social phobia and 
generalized anxiety disorders (National institute of Health), which have in common excessive or 
inappropriate brain excitability within crucial brain circuits (C. J. Swanson et al. 2005).  
There are several forms of depression: 1) major depressive disorder; 2) dysthymic disorder; 
3) psychotic depression; 4) postpartum depression; 5) season affective disorder. In general these 
disorders are characterized by a combination of symptoms like disability of work, sleep, study and 
enjoy once-pleasurable activities (anhedonia). In some cases like psychotic depression, the 
depressive illness is accompanied  by hallucinations and delusions (National institute of Health). It is 
important to notice that some of these symptoms like anhedonia, hallucinations and delusions are 
symptoms of psychiatric diseases like schizophrenia (Venzala et al. 2012). 
Major depression is a mental illness very often described as a stress-related disorder since 
there is good evidence that both onset and relapse of depressive disorders can be precipitated by 
repeated stress or severe stressful experiences (Venzala et al. 2012) 
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In rat models for depression  alterations in neurotransmitter levels, namely increased levels 
of glutamate and decreased levels of dopamine and GABA, have been found. Consequently, in this 
type of disorder there is  also excessive excitatory neurotransmission (Venzala et al. 2012).  
As all of these disorders have in common inappropriate brain excitability and since glutamate 
is the major excitatory neurotransmitter in the brain, huge research efforts are devoted to novel 
treatments that could modulate glutamate functions (C. J. Swanson et al. 2005).  Since the mGlu2 
receptor is present in areas of the brain that are thought to play a critical role in anxiety disorders 
(Walker & Davis 2002) and psychosis  among other CNS disorders (Galici et al. 2005), this receptor in 
particular is considered a promising target. 
 
1.4. mGlu2 receptor as a drug target 
1.4.1. Expression 
mGlu2 receptors are expressed presynaptically in most brain regions (Chavez-noriega et al. 
2005) and spinal cord areas. In situ hybridization, immunohistochemistry and autoradiography have 
confirmed expression of mGlu2/3 receptors in hippocampus, olfactory bulb, neocortical regions and 
cerebellar Golgi neurons, with lower levels of expression in thalamic nuclei and striatum (Figure 7) 
(Hervé Schaffhauser et al. 2003). 
 
Figure 7. Immunoreactivity for mGlu 2 receptors. AOB - accessory olfactory bulb; Cx, neocortex; St, neostriatum 
(Shigemoto & Mizuno 2000) 
mGlu2 receptors are observed not only in somatodendritic 
domains but also in axonal domains. They are also present in 
interstitial glial cells of the pineal gland. Group II receptors are often 
observed in extrasynaptic sites (Figure 8) remote from the active 
zone in preterminal portions of axons and axon terminals and about 
79% of immunoparticles for the mGlu2 receptor in cerebellar Golgi 
cell axons (Shigemoto & Mizuno 2000). 
 
 
Figure 8. Subcellular localization of 
group II mGlu receptors (Shigemoto 
& Mizuno 2000) 
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1.4.2. Function 
Generally, group I receptors potentiate glutamate function, particularly at NMDA receptors, 
whereas group II and III receptors decrease synaptic transmission and glutamate release in the 
hippocampus (Macek et al. 1996; Kantrowitz & Javitt 2010). So, pharmacological activation of group 
II mGlu receptors potently inhibits excitatory glutamatergic synaptic transmission in several brain 
areas relevant to several pathophysiologies via a presynaptic site of action (Chavez-noriega et al. 
2005). It is important to note that group II mGlu receptors activation reduce transmission at 
inhibitory synapses in the accessory olfactory bulb (P J Conn & J. P. Pin 1997), hippocampal area CA3 
in young animals (Poncer et al. 1995), and thalamus (Salt & Eaton 1995). 
 
1.4.3. Signal transduction 
As stated above, group II mGlu receptors are negatively coupled to adenylyl cyclase (C. J. 
Swanson et al. 2005), and inhibit cAMP formation stimulated by either forskolin (activator of  
adenylyl cyclase) or a GS-coupled receptor. This effect is inhibited by pertussis toxin (PTX) treatment 
of the cells, which indicates the involvement of a Gi-type of G-protein (P J Conn & J. P. Pin 1997). 
Inhibition of the cAMP cascade occurs in neuronal and glial cells (L Prézeau et al. 1994).  
Activation of mGlu2 receptors is also linked to rapid-onset regulation of various channels 
including calcium channels (S. Choi & Lovinger 1996) and G-protein-coupled inwardly rectifying K+ 
channels (Knoflach & J. a Kemp 1998)  depending on neuronal cell types (Shigemoto & Mizuno 2000). 
 
1.4.4. Pharmacology 
 
Agonists 
The structural analogy to glutamate, with the presence of a distal carboxylic acid to the 
amino acid functionality, strongly influences the properties of competitive or orthosteric ligands, 
which bind to the same site as glutamate, and limits considerably their capacity to cross membranes 
by passive diffusion. As a consequence, most of these compounds have a poor oral bioavailability, 
and do not readily cross the blood-brain-barrier (F Gasparini & Spooren 2007). 
Examples of these glutamate analogs (in rank of order of potency) are (2S, 1’R, 2’R, 3’R)-2-(2, 
3-dicarboxycyclo-propyl) glycine (DCG-IV, Figure 9) = L-CCG-I > 2R,4R-4-aminopyrrolidine-2, 4-
dicarboxylate (APDC, Figure 9) > glutamate > 1S, 3S-ACPD > 1S, 3R-ACPD > 4C3HPG  (Figure 9) > 
ibotenate (P J Conn & J. P. Pin 1997). Only compound 2R, 4R - APDC is a specific group II agonist (D.D 
Schoepp et al. 1995). See Table 3 for compounds potency. 
More recently identified orthosteric agonists for the mGlu2/3 receptor are an exception for 
the cases mentioned above. These small molecular weight ligands (LY354740, LY379268 and 
LY404039) (Rorick-Kehn et al. 2007) display potent agonist activity at mGlu2/3 receptors, are orally 
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bioavailable and enter the brain in preclinical models (J A Monn et al. 1999). It was also showed that 
these molecules have efficacy in preclinical models of psychosis and anxiety (Gregory et al. 2011; C. J. 
Swanson et al. 2005; Trabanco et al. 2011). The neurochemical evidence for the ability of group II 
activation to reverse the effects of psychotomimetic agents has been supplemented by their ability 
to reverse the behavioral effects in several animal models that are used to predict efficacy of 
potential antipsychotic agents although there are some exceptions to this effect depending on which 
compound is being studied, which behavioral paradigm is being tested and what strain of animal is 
being used (Vinson & P Jeffrey Conn 2012). 
LY2140023 (Figure 9) which is the oral prodrug of the agonist LY404039 (Figure 9), has shown 
beneficial effects on positive and negative symptoms of schizophrenia without the side effects 
associated with typical and atypical antipsychotics (Patil et al. 2007). Recently this compound has 
entered phase II/III trials for schizophrenia. Other compounds, LY354740 (Figure 9) and LY379268 
(Figure 9) have clinical efficacy in treating panic attacks and generalized anxiety disorders (Gregory et 
al. 2011), which can be seen by preclinical animal models of anxiety (Trabanco et al. 2011). Another 
group II agonist is MGS0028 (Hervé Schaffhauser et al. 2003). Nevertheless, only LY404039 is 
currently still in clinical development. 
 
Figure 9. Structures of some glutamate group II receptors agonists [adapted from (P Jeffrey Conn et al. 2009; Trabanco et 
al. 2011)] 
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Antagonists 
The rank order of potency of mGlu2 receptor antagonists is 2S-2-amino-2-(1S,2S-2-
carboxycyclopropan-1-yl)-3-(xanth-9-yl) propionic acid (LY341495) = (1R,2R,3R,5R,6R)-2-amino-3-
(3,4-dichlorobenzyloxy)-6-fluorobicyclo [3.1.0] hexane-
2,6- dicarboxylic acid (MGS0039) > (2S, 1’S, 2’S, 3’R)- 2-
(2’-carboxy-3’-phenylcyclopropyl) glycine (PCCG-IV, 
Figure 10) > 2S, 4S- 2-amino-4-(4, 4-diphenylbut-1-yl)-
pentane-1, 5-dioic acid (ADPD) > α-methyl-L-CCG-I 
(MCCG-I, Figure 10) > α-methyl-4-
phosphonophenylglycine (MPPG) > α-methyl-4-
sulfonophenylglycine (MSPG) > α-methyl-4-tetra- zoylphenylglycine (MTPG) (P J Conn & J. P. Pin 
1997). See Table 3 for compounds potency. 
The therapeutic significance of mGlu2 receptor antagonists has not been widely investigated. 
However, studies of some selective competitive group II mGlu receptor antagonists, which include 
LY341495 and MGS0039, have suggested that these kind of compounds exhibit antidepressant-like 
activity and anti-obsessive-compulsive disorder-like effects in animal models (Chaki et al. 2004; 
Hemstapat et al. 2007). 
Table 3. Summary of mGlu2 receptor agonists and antagonists potency (EC50 and IC50) 
Agonist 
Potency 
(μM) 
Antagonist 
Potency 
(μM) 
Glutamate 4-20 MPPG 100 
Ibotenate 35-250 MSPG 250 
1S, 3R-ACPD 18 MTPG 450 
1S, 3S-ACPD 13 MCCG-I 84 
L-CCG-1 0.3-0.4 PCCG-IV 8 
DCG-IV 0.3 ADPD 18.1 
2R, 4R-APDC 3 LY341495 0.02 
4C3HPG 20-50 MGS0039 0.02 
 
Figure 10. Structures of some glutamate group II 
receptors antagonists [adapted from (Trabanco et 
al. 2011)] 
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1.5. Allosteric modulation 
The majority of GPCR-based drug discovery programs have failed to yield highly selective 
compounds. This is due to the traditional approach that targets the endogenous ligand (orthosteric)-
binding site, to either mimic or block the actions of the endogenous neurotransmitter or hormone in 
a competitive manner (Gregory et al. 2011). Some studies showed that orthosteric agonists used 
activate both mGlu2 and mGlu3 receptors, and induced tolerance in one rodent model (Galici et al. 
2005). Preclinical studies indicate that the mGlu2 receptor is likely to be responsible for clinical 
efficacy (Fell et al. 2008) showing that sub-type specificity is needed. Therefore it is important to 
search for alternative structural compound classes to inhibit or activate mGlu receptor function (F 
Gasparini & Spooren 2007). Though, an alternative approach is to target allosteric sites. These sites 
are different from the orthosteric site, and their activation leads to enhancement or inhibition of 
receptor activation (Gregory et al. 2011). 
The validity of GPCR allosteric modulators was demonstrated with two compounds that have 
entered the market. In 2004, one allosteric enhancer (cinacalcet) of the calcium-sensing receptor 
(CaSR) was approved for the treatment of hyperparathyroidism (Lindberg et al. 2005), and in 2007 an 
allosteric inhibitor (maraviroc) of the chemokine receptor CCR5 was approved for the treatment of 
HIV infections (Dorr et al. 2005).  
One of the best known GPCR allosteric modulator is benzodiazepine. This is an allosteric 
modulator of GABAA receptors and is known for its effects on the treatment of anxiety and sleep 
disorders (P Jeffrey Conn et al. 2009).  
Nowadays, for CNS disorders , allosteric modulation receives major attention in drug 
discovery (Gregory et al. 2011).  
 
1.5.1. Allosteric (PAM and NAM) vs Orthosteric 
In the case of mGlu receptors the orthosteric binding site is located in the N-terminal 
domain. The compounds that compete with endogenous agonists for this site are called competitive 
agonists or antagonists (F Gasparini & Spooren 2007). While the allosteric modulators bind to an 
allosteric site (topographically distinct from the orthosteric site) and modulate (increase or decrease) 
the response of an orthosteric ligand (P Jeffrey Conn et al. 2009; Vinson & P Jeffrey Conn 2012) and 
for the mGlu receptors is located in the less conserved transmembrane regions (Figure 5) (Urwyler 
2011; Vinson & P Jeffrey Conn 2012).  
Positive allosteric modulators (PAM) can increase the response of the endogenous ligand 
while negative allosteric modulator (NAM) decreases the response. Also, there are neutral allosteric 
ligands which bind to the allosteric site but have no effects on the response of the orthosteric ligand.  
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Because allosteric modulators bind to sites on a given receptor different from those to which 
orthosteric ligands bind, they are in general structurally diverse and not at all related to orthosteric 
ligands, particularly the endogenous natural agonists (Urwyler 2011). 
 
1.5.2. Mode of action 
The binding of an allosteric ligand to its site will change the three-dimensional conformation 
of the receptor (Gregory et al. 2011; Urwyler 2011) and induce a modulation (increase or decrease) 
of the response to the agonist that binds to the orthosteric site (Vinson & P Jeffrey Conn 2012). 
Basically, a receptor occupied by an allosteric ligand can be visualized as a “new” receptor type, with 
a unique behavior (P Jeffrey Conn et al. 2009). There are models that explain allosteric modulation. 
The simplest allosteric GPCR model assumes that binding of an allosteric ligand to its site modulates 
only the affinity of the orthosteric ligand and vice versa. This model is called the allosteric ternary 
complex model and is represented in Figure 11. In this model a value of 0<α<1 indicates that the 
binding of an allosteric ligand inhibits the binding of the orthosteric ligand (negative cooperativity), 
whereas values of α>1 indicates positive cooperativity (allosteric modulator promotes the binding of 
orthosteric ligand). On the other hand, α=0 indicates neutral cooperativity (the two sites are 
conformationally linked) (Gregory et al. 2011). It is important to know that cooperativity refers to the 
binding of two or more molecules of the same ligand to a receptor complex to initiate a response. It 
is also used in a less strict sense to describe the allosteric interaction between more than one 
molecule of any chemical type on a receptor complex (P Jeffrey Conn et al. 2009). 
 
Figure 11. Allosteric ternary complex model. R – receptor; A- agonist; B – modulator; KA – orthosteric ligand dissociation 
constant; KB – allosteric ligand dissociation constant; α – cooperativity factor (Gregory et al. 2011) 
 
In the allosteric ternary complex model the stimulus that is generated by the ARB ternary 
complex is assumed to be no different to that reported by the binary AR complex (Gregory et al. 
2011). 
However, an allosteric modulator in the GPCR can perturb signaling efficacy not only by 
effects on orthosteric ligand binding affinity. In the case of mGlu receptors the majority of allosteric 
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modulators influence orthosteric efficacy without affecting the affinity. This effect is due to the 
different orthosteric and allosteric binding sites localization (Gregory et al. 2011).  
Furthermore, there are different modes of actions for different allosteric modulators. Some 
allosteric modulators can modulate orthosteric ligand affinity and/or efficacy and other allosteric 
ligands can directly perturb signaling in their own right (Figure 12) (P Jeffrey Conn et al. 2009). These 
compounds that act as agonists on their own are called allosteric agonists and add an additional layer 
of complexity to treatment options (Gregory et al. 2011; Hervé Schaffhauser et al. 2003). 
      
Figure 12. Modes of action of allosteric modulators (P Jeffrey Conn et al. 2009) 
 
Since an allosteric modulator can have differential effects on affinity versus efficacy, 
alternative models have been developed to describe allosteric interactions (Gregory et al. 2011). 
Figure 13 presents an “operational model of allosterism”. This model describes both 
allosteric modulation of affinity and efficacy and incorporates allosteric agonism (Leach et al. 2007). 
While the previous models do not fit to real experimental data, this model combines both 
mechanistic and empirical parameters to facilitate quantification of experimentally-derived allosteric 
drug properties in a manner that can facilitate structure-activity studies (P Jeffrey Conn et al. 2009). 
In this model, allosteric modulation is governed by two parameters (α and β) which can alter 
for each set of interacting ligands (Gregory et al. 2011). 
Figure 13. Operational Model of Allosterism. S – stimulus; 
AR – agonist bound; BR – modulator bound; ARB – ternary 
complex; α – cooperativity factor; β – allosteric modulation of 
efficacy; τA  and τB – ability of the orthosteric and allosteric 
ligands, respectively, to engender receptor activation 
(incorporate the efficacy of each ligand, the total density of 
receptors and the stimulus-response coupling efficiency; Em – 
maximal possible system response; n – slope factor (Gregory 
et al. 2011). 
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As a summary one can say that allosteric modulators exhibit one or more of the following 
pharmacological properties: affinity modulation: conformation change can impact the orthosteric 
binding site such that either association and/or dissociation rate of an orthosteric ligand is modified; 
efficacy modulation: allosteric effect can change intracellular responses which lead to a change in 
signaling capacity of an orthosteric ligand; agonism/inverse agonism: the allosteric modulator can 
perturb receptor signaling in a positive or negative way (P Jeffrey Conn et al. 2009; May et al. 2007; 
Hervé Schaffhauser et al. 2003). 
 
1.5.3. Group II mGlu receptors NAMs and PAMs 
Two main chemical classes of positive allosteric mGlu2 receptor modulators were originally 
described and have become standard tool compounds pyrimidylsulfonamides, represented by N-(4-
(2-methoxy-phenoxy)-phenyl-N-(2,2,2-trifluoroethylsulfonyl)-pyrid-3- ylmethylamine (LY487379) and 
indanone compounds, represented by biphenylindanone A (BINA) (Urwyler 2011).  These compounds 
are low molecular weight, structurally different from glutamate and are selective mGlu2 receptor 
positive modulators (PAMs) (B. A. Rowe et al. 2008; Hervé Schaffhauser et al. 2003). They increase 
the ability of the mGlu2 receptor to activate G-proteins by inducing a leftward shifts of the glutamate 
concentration response curve and potentiating the ability of group II selective agonists to reduce 
transmission at a number of glutamatergic synapses (Hervé Schaffhauser et al. 2003). BINA is a more 
potent and brain penetrable than LY487379, and its use in vivo confirmed potential anti-psychotic 
effects (F Gasparini & Spooren 2007). 
The finding of selective mGlu2 receptor PAMs was important because it allows the 
development of compounds that selectively potentiate mGlu2 but not mGlu3 receptors (Hervé 
Schaffhauser et al. 2003).  
Figure 14 shows the structure of additional mGlu2 PAM molecules, which have a similar 
profile as LY487379. 
 
Figure  14. mGlu2 receptor PAMs [adapted from (F Gasparini & Spooren 2007)] 
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Other types of mGlu2 PAMs are represented in Figure 15. Compounds A, B, C and D are 
selective for mGlu2 receptor and increase both potency and efficacy of glutamate. On the other 
hand, compounds E, F, G and H are mGlu2 receptor potentiators and weak mGlu3 receptor positive 
allosteric modulators (B. A. Rowe et al. 2008). 
There are also allosteric compounds, mGlu2 NAMs, (Figure 16) that have shown to inhibit 
agonist stimulated GTP-γ-[35S] binding (F Gasparini & Spooren 2007).  
Also Hemstapat et al. found that three compounds (MNI-135, MNI-136 and MNI-137) are 
selective mGlu2/3 NAMs. However, none of these compounds provided sufficient selectivity 
between the group II mGlu receptors to be useful for differentiating between these group subtypes.  
Taking in account the effects achieved with orthosteric antagonists, it could be speculated 
that mGlu2 receptor NAMs could improve cognitive and memory disturbances (Higgins et al. 2004). 
 
 
Figure  15.  Chemical structures of mGlu2 PAMs described by (B. A. Rowe et al. 2008) 
  
 
Figure  16. mGluR2 NAMs (F Gasparini & Spooren 2007) 
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1.5.3.1. Group II mGlu receptors allosteric binding site 
Figure 17, shows the three-dimensional structure of the mGlu2 receptor based on X-ray 
crystal structure of the bovine rhodopsin receptor. The N-terminal extracellular, glutamate binding 
site is represented as a clamshell-shaped object. The transmembrane domains are depicted as α-
helical structures. The residues (Ser 688, Gly 689 and Asn 735, respectively) depicted in the TM IV 
and V domain have been shown to be involved in the binding of LY487379 (Hervé Schaffhauser et al. 
2003).  
 
 
 
 
 
 
Figure  17. Schematic diagram of the three-dimensional protein structure of the mGlu2 receptor [adapted from (Hervé 
Schaffhauser et al. 2003)] 
 
In addition, Hemstapat et al. verified that Asn 735 is also critical for the binding of BINA and 
Rowe et al. described that these residues are, as well, involved in the binding of other PAMs. 
Although this proves that these residues are critical it does not mean they are the only three residues 
involved in the activity of these compounds (B. A. Rowe et al. 2008). These studies will be discussed 
in more detail in section 1.6.   
Previous studies demonstrate that some of the critical residues for PAM binding do not seem 
to affect binding of some NAM compounds (MIN-135, MNI-1366 and MNI-137), indicating that the 
binding site for NAMs and PAMs for mGlu2 seems to be different  (Hemstapat et al. 2007).  
 
1.5.4. Measurement of PAM and NAM in vitro 
In order to identify allosteric modulators in vitro assays that allow the characterization of the 
functional activity of agents acting at the receptor have to be used. Related to group II and III mGlu 
receptors (coupled to Gi type of G-proteins), functional assays involving GTP-γ-35S binding and 
determination of cAMP concentration changes can be used to identify allosteric ligands (Figure 18B) 
(F Gasparini & Spooren 2007). 
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The development of these functional assays allowed the screening of large chemical libraries 
and the identification of numerous ligands with no structural analogy to glutamate (natural ligand) 
acting as NAM or PAM (F Gasparini & Spooren 2007). 
 
1.5.5. Advantages 
PAMs offer an attractive therapeutic approach for the activation of GPCRs because they 
would be efficacious only in the presence of endogenous agonist (if they do not display any direct 
agonism) (P Jeffrey Conn et al. 2009) and for that they may elicit less tachyphylaxis (acute decrease in 
the response to a drug after administration) (Hervé Schaffhauser et al. 2003; Gregory et al. 2011). 
The use of allosteric modulators is also important because it can overcoming receptor desensitization 
that occurs after persistent treatment with agonists (May et al. 2007; J. P. Pin et al. 2001; Urwyler 
2011). Moreover, such allosteric modulators maintain activity dependence and both temporal and 
spatial aspects of endogenous physiological signaling (Urwyler 2011; P Jeffrey Conn et al. 2009), and 
for that side effects may be reduced (Urwyler 2011). Via this way, one may expect a better 
therapeutic outcome compared to sustained blockade or activation achieved by orthosteric ligands 
(Gregory et al. 2011). 
Moreover, since their binding sites are outside of the highly conserved agonist binding site, 
they offer the potential for highly selective ligands, which has been difficult to achieve. Alternatively, 
selectivity could be achieved by combining both orthosteric and allosteric pharmacophores within 
the same molecule to yield a novel class of bitopic GPCR ligand (P Jeffrey Conn et al. 2009; Gregory et 
al. 2011; Hervé Schaffhauser et al. 2003). 
Also, allosteric modulators with limited positive or negative cooperativity allow a high degree 
of titratability of the pharmacological effect, meaning that large doses of allosteric modulator can be 
administered with a lower propensity towards target-based toxicity than orthosteric agonists or 
antagonists. Furthermore, limited cooperativity modulators can allow for a subtle re-setting of 
endogenous agonist activity (P Jeffrey Conn et al. 2009). 
Figure 18. Group II and III mGluR signal transduction pathways and methods to see efficacy (F Gasparini & Spooren 2007) 
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Another advantage is the fact that allosteric modulators could be useful in diseases states in 
which the level of the endogenous ligand is attenuated. In these cases, administration of a 
potentiator could achieve normal agonist responses (B. A. Rowe et al. 2008). 
 
1.5.6. Disadvantages 
It is clear that, although, both PAMs and NAMs rely upon the presence of the endogenous 
ligand, allosteric modulators offer a variety of advantages over orthosteric counterparts. However, 
the drug discovery centered on small molecules, either allosteric and orthosteric, share common 
problems, including solubility and formulation, generation of active metabolites, clearance and lack 
of brain penetrance (Gregory et al. 2011; Hervé Schaffhauser et al. 2003). Moreover, the fact that 
allosteric sites are not conserved, which permits receptor subtype selectivity, also may result in 
species differences, which may lead to problems when using  rodent models in drug discovery 
(Urwyler 2011). 
Another disadvantage lays in the activity-dependence of allosteric modulators. This fact, 
already discussed as an advantageous can become a handicap in some diseases like 
neurodegenerative disorders in which the loss of neurons can result in decreased availability of the 
endogenous ligand (Urwyler 2011). 
 
1.6. Mutagenesis Studies on mGlu receptors 
Mutagenesis studies of GPCRs have been extensively used to depict the molecular 
determinants of the receptor involved in the functional coupling, both physical interaction and 
activation, to G-proteins   (Gether 2000; Wess 1998). This type of studies has demonstrated the 
existence of critical regions whose alteration differentially affects the intracellular signaling cascade 
triggered by the agonist. It has also been shown that distinct domains of the receptor are involved in 
the functional coupling with multiple G-proteins (Hermans 2003).  
Site-direct mutagenesis is furthermore used to identify important residues and binding 
determinants for allosteric modulators (Gregory et al. 2011). The first allosteric modulator to be 
identified was CPCCOEt, a NAM of mGlu1. Litschig et al. identified the two amino acids in the 7TMD 
of mGlu1 responsible for the selective action of this compound.  They were able to reach this 
conclusion because of the selectivity of CPCCOEt for mGlu1 relatively to mGlu5.  Hence, they switched 
crucial residues in mGlu1 to their corresponding residues of mGlu5 resulting in a gain of function for 
these mGlu1 selective modulators at mGlu5 receptors (S Litschig et al. 1999). In other studies some 
amino acids were identified as important for binding of allosteric modulators in the hmGluR2 (as 
mentioned before in the section 1.5.3.1). One of the studies was done by Rowe et al., they prepared 
mutant receptors by exchanging either segments, single amino acids residues, or multiple amino 
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acids residues between hmGluR3 and hmGluR2. They determined that the exchange of the mGluR2 
amino acid residues present in TMIII-V (Leu656 to Arg750) with homologous hmGluR3 sequences 
resulted in a complete loss of the potentiatior activity of MRLSD-650 (mGluR2 specific). This same 
domain was previously identified as the binding site for other mGluR2 potentiator LY487379 (Hervé 
Schaffhauser et al. 2003).  
More mutagenesis studies on mGlu receptors followed, with the main goal of investigating 
the molecular determinants of the allosteric modulator-receptor interactions (Table 4). The 
identification of these amino acids may be important to improve selectivity and potency of allosteric 
compounds (Pagano et al. 2000).  
In most of these studies, suggestions for amino acid mutations are based on sequence 
alignment, homology modeling and docking with receptors which structure has already been 
crystallized (Gregory et al. 2011). 
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1.6.1. Sequence alignment and homology modeling 
High-resolution 3-dimensional structures of proteins provide detailed information of the 
form and function of the molecular level. This is useful to describe aspects of protein structure 
involved in physiological processes and to visualize the connections between their ligands and to 
small molecule drugs (Congreve & Marshall 2010).  
For several mGlu receptors, the extracellular N-terminal domain has been crystallized. 
However, the structure of the hepta-helical transmembrane domain of the receptor has yet to be 
determined. In this case, homology modeling with class A GPCR templates has been shown to 
provide substantial insight into the transmembrane region of these receptors (Gregory et al. 2011). 
The main goal of protein modeling is to predict a structure from its sequence with an 
accuracy that is comparable to the best results obtained experimentally. This allows to use rapidly 
generated in silico protein models in all the contexts where only experimental structures provide 
solid bases, like structre-based drug design, analysis of protein function, interactions, antigenic 
behavior, and rational design of proteins with increased stability or novel functions. Homology 
modeling is based on two major observations:  a) the structure of a protein is uniquely determined 
by its amino acid sequence;  b) the structure is more stable and changes much slower than the 
associated sequence, for that, similar sequences adopt identical structures, and distantly related 
sequences still fold into similar structures . In practice, homology modeling is a multistep process 
that can be summarized in seven steps: 1. Template recognition and initial alignment; 2. Alignment 
correction; 3. Backbone generation; 4. Loop modeling; 5. Side-chain modeling; 7. Model 
optimization; 8. Model validation (Krieger et al. 2003). 
 The Rhodopsin (class A) GPCR is a visual pigment and has for several years conferred a 
structural template for other GPCRs, including the assignment of secondary structural elements and 
the location of highly conserved amino acids.  The 3D structure of this receptor was determined by 
Palczewski et al. from diffraction data extending to 2.8 angstroms resolution (Figure 19). The lengths 
of the seven transmembrane helices and of the three extracellular loops are more or less the same 
for most of the family members. The other regions present some variations, reflecting the specificity 
of each receptor for either its ligand or G protein (Palczewski et al. 2000). It is important to note that 
the sequence similarity between class C GPCRs and class A GPCRs is low (Lundström et al. 2011), 
however, by experimental work it was found that the allosteric binding site of mGlu receptors is 
overlapping with the retinal binding pocket of rhodopsin, which implies a conservation of ligand 
binding. These findings were complemented with the docking of known allosteric mGluR ligands to 
computationally generated models of different mGluR subtypes based on rhodopsin structure. It was 
also shown that positive and negative modulators docked preferentially to the active and inactive 
models of the receptor, respectively, suggesting that the modulators can be distinguished by their 
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affinities for the active or inactive conformation of the receptor (Yanamala & Klein-Seetharaman 
2010). 
 
Figure 19. Three-dimensional view of rhodopsin GPCR (Palczewski et al. 2000) 
 
Since the bovine rhodopsin GPCR crystal structure, six additional mammalian GPCR crystal 
structures have become available (see Table 5), which allowed the development of hight-throughput 
homology modeling of GPCRs, enriching the understanding of the transmembrane region of these 
receptors (Gregory et al. 2011). 
 
        Table 5.  Summary of GPCRs which structure has been crystallized 
Receptor GPCR family References 
β2-adrenergic A Cherezov et al. 2008 
A2A adenosine  A Jaakola et al. 2009 
CXCR4 chemokine A Wu et al. 2010 
Dopamine D3 A Chien et al. 2010 
Histamine H1  A Shimamura et al. 2012 
S1P1 Sphingosine 1-phosphate  A Hanson et al. 2012 
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1.7.  Goal of the project 
 
Janssen Pharmaceutica has an mGlu2 receptor PAM in clinical development for the 
treatment of schizophrenia. Additionally, as part of an internal mGlu receptor PAM program, other 
compounds were identified as potentially important. It is important to clarify the PAM-receptor 
interactions to understand the mechanisms through which these compounds produce their effects. 
Therefore it is of large interest to characterize the amino acids that are critical for the binding and/or 
activity the of PAM compounds. 
In order to reveal the PAM binding site, homology modeling and docking of mGlu2 receptor 
PAM was performed in parallel with site-directed mutagenesis. Mutant mGlu2 receptors were 
generated and the impact of these mutations on activity and affinity of various structurally different 
PAMs was evaluated. Activity was determined using [35S]GTP S experiments, while binding was 
assessed with an in-house generated [3H]mGlu2 PAM molecule.  This study is an important 
contribution for the mapping of the allosteric binding site of mGlu2 receptors.  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. Materials and Methods 
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2.1. Materials 
The 24 PAMs tested in this study were synthesized at Janssen Pharmaceutica and dissolved in 
100% of dimethyl sulphoxide (DMSO). L-glutamate was purchased from Aldrich® Chemistry. The 
radioligand [3H]-LY341495 was purchased from American Radiolabeled Chemicals, Inc. (St. Louis, MO, 
USA), the radioligand [3H]JNJ-46281222 was synthesized at Janssen Pharmaceutica  and Guanosine 
5’-(γ-thio)triphosphate [35S]- was purchased from Perkin Elmer® (Boston, MA, USA).The monoclonal 
anti-metabotropic glutamate receptor 2 [mG2Na-s] antibody Ab15672 was purchase from Abcam 
(Cambridge, UK). Mutant mGlu2 receptor cDNA constructs were prepared by GeneArt® (Life 
Technologies). 
 
2.2. Positive allosteric modulators tested 
The 24 compounds tested in this study are part of an internal mGluR2 PAM program and are 
divided in 7 different chemical classes: 1,5-pyridone, 1,4-pyridone, azetidine, imidazopyridine, 
isoquinolone, pyridazine and triazolopyridine. These compounds were identified by lead optimization 
of hits originating from high-throughput screening through a calcium mobilization assay performed 
on the mGlu2 receptor. In addition, 3 reference compounds were used: BINA (Galici et al. 2006), 
THIIC (LY2607540) (Fell et al. 2011) and TEMPS (LY487379) (H Schaffhauser et al. 1998). Appendix 2 
summarizes the chemical classes and name of each compound used in this study. 
 
2.3. Selection of amino acid mutations: sequence alignment and building of an mGlu2 
receptor homology model 
The identification and selection of the amino acids as targets for mutagenesis studies was 
based on three hypotheses: 1) sequence alignment of the entire mGlu family; 2) sequence 
comparison between the mGlu2 and mGlu3 receptor; 3) binding orientation of an mGlu2 PAM with 
an mGlu2 receptor model generated by modeling homology. This work was performed by Gary 
Tresadern, head of Molecular Informatics.  
1) The full length receptor sequences were aligned in a progressive manner using Molecular 
Operating Environment (MOE) Protein Align tool (Chemical Computing Group, Canada). In a 
first step, members of each mGlu subgroup were aligned to each other. Subsequently the 
three subgroups were aligned to each other using constraints for class C GPCRs. Figure 20A 
shows the aligned 7-TM’s, highlighting the residues identified as important from literature 
mutagenesis studies.  
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2) The mGlu2 and mGlu3 sequences were compared (Figure 20B) to 
identify which amino acids differ and are therefore potentially 
important for the selective binding of mGlu2 receptor PAM 
compounds. The main differences are seen in the extracellular 
portion of TM3, TM4, EL2 and TM5. 
 
3) The mGlu2 sequence was aligned to that of the rhodopsin and β2-
adrenergic receptor and the X-ray structure 2RH1 was 
subsequently used to build an mGlu2 receptor homology model. 
The 3D models of mGlu2 receptor were built using the Homology Model tool in MOE. In 
order to establish a possible binding mode of mGlu2 receptor PAMs, they were docked into 
the mGlu2 receptor model, and amino acids were selected based on their proximity to the 
ligand (Figure 21). 
 
Overall, amino acids from TM2, TM4, TM5 and EL2 in a total of 40 amino acids were selected 
for site-direct mutagenesis (37 single point mutations, one double and two triple mutations were 
prepared). 
 
 
 
 
 
 
A B 
Figure 20. Alignment of mGluR 7TMs. A- Residues highlighted in red boxes have been identified as important from literature 
mutagenesis studies. B-Comparison between hmGluR2 and hmGluR3, with highlighted differences.  
Figure 21. Ribbon diagram of the 
binding mode of a reference 
PAM compound in the mGlu2 
model structure built from β2-
adrenergic template 
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Table 6. mGlu2 receptor mutagenesis constructs. The wild type (WT) and the substituting amino acids are indicated, as 
well as their position and the receptor region where they are located. TM – transmembrane; EL – extracellular loop. 1 – 
Sequence alignment and 1.1-mGlu2/3 comparison; 2-Homology modeling and docking and 2.1 – mGlu2/3 comparison 
Receptor 
region 
Name WT AA Position Mutation 
WT 
codon 
mutant 
codon  
TM2 
C616S Cys 616 Ser TGC TCC 
1.1 
I622F Ile 622 Phe ATC TTC 
TM3 
T641S Thr 641 Ser ACC TCC 
1.1 
A642S Ala 642 Ser GCC TCC 
R636A Arg 636 Ala CGT GCT 1 and 2 
L639A Leu 639 Ala TTG GCG 2 
F643A Phe 643 Ala TTC GCC 1 and 2 
S644A Ser 644 Ala TCT GCT 2.1 
R635A Arg 635 Ala AGA GCG 1 
TM4 
S688L Ser 688 Leu TCG TTG 
1 
G689V Gly 689 Val GGC GTC 
V700L Val 700 Leu GTC CTC 2.1 
A681F Ala 681 Phe GCC TTC 1.1 
I693M Ile 693 Met ATT ATG 
1.1 V695S Val 695 Ser GTG TCG 
A696V Ala 696 Val GCC GTC 
S688L 
G689V 
 Ser  688 Leu      TCG     TTG 1 
EL2 
H723V Gly 689 Val GGC GTC 1 and 2.1 
G706R Gly 706 Arg GGA CGA 
1.1 
E708Y Glu 708 Tyr GAG TAC 
A710L Ala 710 Leu GCC CTC 
P711A Pro 711 Ala CCC GCC 
V716T Val 716 Thr GTG ACG 
T718I Thr 718 Ile ACC ATC 
TM5 
N735D Asn 735 Asp AAT GAT 1 
D725A Asp 725 Ala GAT GCT 2 
L732A Leu 732 Ala CTG GCG 1 and 2 
M728A Met 728 Ala ATG GCG 
1 S731A Ser 731 Ala AGC GCC 
V736A Val 736 Ala GTG GCG 
A726S Ala 726 Ser GCC TCC 
1.1 G730I Gly 730 Ile GGC ATC 
A733T Ala 733 Thr GCC ACC 
A740I Ala 740 Ile GCC ATC 
TM6 
W773A Trp 773 Ala TGG GCG 1 and 2 
F776A Phe 776 Ala TTC GCC 2 
F780A Phe 780 Ala TTC GCC 1 and 2 
TM7 V798A Val 798 Ala GTG GCG 1 
TM3/4/EL2 
S644A 
V700L 
H723V 
Ser 
Val 
His 
644 
700 
723 
Ala 
Leu 
Val 
TCT 
GTC 
CAC 
GCT 
CTC 
GTC 
2.1 
TM4/5 
S688L 
G689V 
N735D 
Ser 
Gly 
Asn 
688 
689 
735 
Leu 
Val 
Asp 
TCG 
GGC 
AAT 
TTG 
GTC 
GAT 
1 
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2.4. Cell culture 
CHO-K1 cells (ATCC: CCL-61) were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS: HyClone®, Thermo Scientific, 
Cramlington, UK) and 2% (v/v) Solution A. This solution is composed of Penicillin G (Serva, 
Bioconnect, Huissen, The Netherlands) 5.1E6 IU/L, Streptomycin sulphate (Serva) 5 g/L, Pyruvic acid 
(Sigma) 5.5 g/L and L-Glutamine (Sigma, St. Louis, MO, USA) 14.6 g/L. Cells were kept at 37oC in a 
humidified atmosphere with 5% CO2.  
 
2.5. Transient Transfection of human mGlu2 receptor cDNA into CHO-K1  
Transfections were done using a liposome-based method (Lipofectamine), which delivers 
DNA into cells. The cationic part of the lipid molecule associates with the negatively charged nucleic 
acids, resulting in compaction of the nucleic acid in a liposome/nucleic acid complex. For cultured 
cells, an overall net positive charge of the liposome/nucleic acid complex normally results in higher 
efficiency, because this allows closer association of the complex with the negatively charged cell 
membrane. After endocytosis the complex appears in the endosomes and later in the nucleus 
(Chesnoy & Huang 2000).  
 
Procedure 
CHO-K1 cells were seeded in 145 cm2 Petri dishes at a density of 2.9E6 cells per plate (20000 
cells/cm2) in DMEM supplemented with 10% heat-inactivated FBS and 2% solution A. After 24h, 
confluence of 50-70%  was reached and human mGlu2 (hmGlu2) receptor cDNA, both WT (native 
form of the hmGlu2 receptor) and mutated, was transiently transfected into cells using 
Lipofectamine (InvitrogenTM), followed by incubation overnight in the same medium, at 37oC and in 
an atmosphere of 5% CO2. One Petri dish was used for the transfection of Enhanced Green 
Fluorescent Protein (EGFP-N1) used as control of transfection efficiency. After a period of 20-24h the 
medium was replaced by fresh medium and 48h after transfection butyrate (f.c. 5 mM) was added to 
each Petri dish.   The transfection efficiency was qualitatively evaluated, 48h after transfection 
through observation of transfected cells with EGFP-N1, using a fluorescence microscope (Axiovert 
135, Zeiss, N.V., S.A.). One day after butyrate addition, the Petri dishes with recombinant cells were 
washed twice with ice-cold phosphate-buffered saline (PBS) and stored at -20oC or used immediately 
for membrane preparation.  
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2.6. Crude membrane preparation  
Receptor-containing membranes are prepared by successive washing, centrifugation, 
homogenizing/rehomogenizing and resuspending of cells. The purpose of centrifugation steps is to 
separate membranes from other cell parts as well as to remove any soluble substance that can 
interfere with the receptor, such as endogenous neurotransmitters and guanine nucleotides which 
may interfere with the in vitro pharmacological assays.    
 
Procedure 
Transfected CHO-K1 cells expressing the wild-type or mutant hmGlu2 receptors were 
collected with a rubber scraper and resuspended in ice-cold 50mM Tris-HCl buffer, pH 7.4. The cell 
suspension was always kept on ice.  After collection, the cell suspension was centrifuged for 10 
minutes at 16000 rpm in a Sorvall RC 5B/RC 28S SS34 at 4°C. The cell pellet was resuspended in ice-
cold 5mM Tris-HCl buffer, pH 7.4, and homogenized using an Ultra Turrax homogenizer (IKA TE5) at 
24000 rpm. Additional ice-cold 5mM Tris-HCl buffer was added and one more centrifugation was 
performed for 20 minutes at 18000 rpm in a Sorvall RC 5B/RC 28S centrifuge at 4°C.  The final pellet 
was resuspended and homogenized in ice-cold 50mM Tris-HCl buffer, using an Ultra Turrax 
homogenizer at 24000 rpm. The resulting membrane suspension was aliquoted in cryovials and 
frozen at -80°C. 
 Protein determination was performed by the Bradford method, using bovine serum albumin 
as standard.   
                               
2.7. Western Blot 
By using a western blot, it is possible to identify specific proteins from a complex mixture of 
proteins extracted from cells. The technique uses three elements to accomplish this task: separation 
by size, transfer to a solid support and marking target protein using a proper primary and secondary 
antibody to visualize.  
Protein separation is done based on molecular weight, and thus by type, through gel 
electrophoresis. These results are then transferred to a membrane producing a band for each 
protein. The transfer is done using an electric field oriented perpendicular to the surface of the gel, 
causing proteins to move out of the gel and onto the membrane. The membrane is then incubated 
with labels antibodies specific to the protein of interest (Mahmood & Yang 2012). 
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Procedure 
 hmGlu2 receptor membranes were thawed and homogenized using the Ultra Turrax 
homogenizer. 200 μl of membrane suspension was transferred to a tube and 400 μl of RIPA buffer 
(150 mM NaCl, 1.0% IGEPAL® CA-630, 0.5% sodium deoxycholate, 0.1% SDS, and 50 mM Tris, pH 8.0, 
Sigma) complemented with phosphatase and protease inhibitors (Roche) was added. The 
supernatant fraction was recovered to a fresh tube and the protein concentration was determined by 
the BCA™ Protein Assay (Sigma-Aldrich). 
 18-well Bio-rad gels were loaded with 3 μg of protein and in each gel 4μl of MagicMark was 
also loaded used for accurate molecular weight estimation directly on western blots. NuPAGE® MOPS 
SDS Running Buffer (Life Technologies) was added. The electrophoresis ran initially at 90 V, after 
which the voltage was increased to 150-190 V. Proteins were blotted for 10 minutes on a 
nitrocellulose membrane through a dry blotting system (Bio-rad).  Membranes were blocked for 1h 
at RT with Non-Fat Dry Milk (NFDM) (Santa Cruz, Technology) (5% w/v) diluted in Tris-buffered saline 
and Tween 20 (TBS-T; 10 mM Tris pH 8.0, 150 mM NaCl and 0.05% v/v Tween 20). After, the 
membranes were incubated with the primary antibody (anti-metabotropic glutamate receptor 2 
antibody; final concentration 0.75 μg/ml) diluted in 5% NFDM in TBS-T, overnight at 4oC, with gentle 
agitation. Membranes were washed in TBS-T, 3 to 5 times (5 min) and incubated for 1h at RT with the 
secondary antibody. Primary antibodies were detected through horseradish peroxidase (HRP) -linked 
secondary antibody (1:10000 in TBS-T, Amersham Biosciences), via SuperSignal® West Dura Extended 
Duration Substrate (Pierce, Thermoscientific). Signals were captured and quantified by 
chemiluminescence (G-box Syngene, Syngene). For reprobing, membranes were stripped of 
secondary antibody with Restore™ Western Blot Stripping Buffer for 15 min with agitation at RT. 
Before incubation with anti-actin (dilution 1:10000), the membranes were washed 3 times (5 min) in 
TBS-T and blocked 1h in 5% NFDM. Actin was used as a housekeeping gene. It works as a loading 
control which is essential for proper interpretation of Western blots. These controls are used to 
normalize the levels of protein detected by confirming that protein loading is the same across the 
gel. 
 
2.8. GTPуS binding assay    
      
Background Theory 
 [35S]GTPуS binding is a functional assay which measures the level of G-protein activation 
after the binding of an agonist to a GPCR. The activation of these receptors leads to an increase in 
guanine nucleotide exchange at the Gα-subunit of G-protein heterotrimers, resulting in the creation 
of Gα-[
35S]GTPуS and Gβу subunits. For this, the binding of [
35S]GTPуS is monitored in the presence of 
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unlabeled GDP. Quantification of Gα-[
35S]GTPуS subunit is possible because [35S]GTPyS is relatively 
resistant to hydrolysis by the intrinsic GTPase of Gα. A slow dissociation from Gα occurs with a 
consequent accumulation in the membrane, enabling the quantification of Gα-[35S]GTPуS. Filtration 
is used to remove the excess of free [35S]GTPуS. 
 This is an attractive assay because guanine nucleotide exchange is a proximal event to 
receptor activation and is not subject to amplification or regulation by other cellular processes (W. 
Thomsen et al. 2005). 
 This assay can, however, not be used to evaluate receptor activation in intact cells because 
[35S] does not cross cell membranes. 
 
Figure 22. Scheme of the [
35
S]GTPyS binding assay principle. a) When an agonist binds to the receptor, GTP is exchanged 
for GDP on the α subunit of the G protein and the complexes Gα-GTP and Gβу activate their cellular effectors. The GTPase 
activity of the Gα subunit hydrolyses GTP to GDP, Gα and Gβу reassemble and the system in turned off. b) When [
35
S]GTPyS 
is present, the exchange for GDP also occurs, but the GTPase activity of the Gα subunit is unable to hydrolyze [
35
S]GTPyS, 
which accumulates during the assay period (Harrison & Traynor 2003) 
 
Procedure 
 hmGluR2-CHO-K1 membranes were thawed on ice and homogenized using the Ultra Turrax 
homogenizer and the protein concentration was measured using the Bradford method (Bio-Rad 
Protein Assay, Bio-Rad Laboratories, Munich, Germany). After, the membranes were diluted to a 
concentration of 10 μg/assay in incubation buffer supplemented with 1 mg/ml saponin. The 
incubation buffer is a mix of 10 mM HEPES acid, 10 mM HEPES sodium salt, 100 mM NaCl, 3 mM 
MgCl2.6H2O and 10 μM GDP, pH 7.4.  
 The volume of 140 μl of membranes was added to a 18 μl of assay buffer, 2 μl of test 
compound (at 100-fold final concentration) and 20 μl of glutamate. To test compounds for their PAM 
effect, 4 μM glutamate (corresponding to the EC20 of glutamate) was used. After membrane addition, 
of the mixture was incubated for 30 minutes at 30oC. At last, 20 μl of [35S]GTPуS (0.1 nM f.c.) was 
added and the total assay mixture was incubated for another 30 min at 30oC. The reaction was 
59 
 
stopped through filtration using Unifilter 96-well PerkinElmer filtermate harvester, in order to 
remove the unbound [35S] GTPyS. The filters were washed 3 times with ice-cold 10 mM NaH2PO4/ 10 
mM Na2HPO4 buffer, pH 7.4, and dried overnight at room temperature. 40 μl of Microscint™O (Perkin 
Ekmer, MA, USA) was added to each well and the plates were sealed. After 15-30 min, radioactivity 
was counted in a Microplate scintillation and luminescence counter (Packard).  
 
2.9. Radioligand Binding Assay 
 
Background Theory 
 Radiolabeled agonists and/or antagonists can be used as ligands in binding studies to 
characterize ligand binding sites of receptors. One of the most important considerations in 
radioligand binding assays is the determination of specific binding. Specific binding can be defined as 
the binding to the receptor of interest and is the total binding minus the non-specific binding, which 
is the binding observed in the presence of an excess of unlabeled drug (blank) that fully blocks the 
receptor of interest. A filtration step (or centrifugation) is required to separate bound and unbound 
radioligand and the radioactivity is measured as disintegrations per minute (DPM) or counts per 
minute (CPM). 
A good radioligand has the following properties: i) high affinity (to favor specific over non-
specific binding); ii) low non-specific binding; iii) high specific activity (to detect low receptor 
densities); iv) receptor specificity.   
 Radioligand binding studies can be done through different approaches depending on the goal 
of the experiment: 
 
Saturation binding 
Two important parameters can be obtained from this type of experiment, the affinity 
(dissociation constant – KD) and the density (maximum number of binding sites - Bmax). By definition, 
KD is the concentration of ligand that will occupy 50% of the receptors.  
In saturation binding experiments, increasing concentrations of the radioligand are added. 
Typically, a range of concentrations equivalent to 10 times below and 10 times higher the (expected) 
KD is used. The high concentrations should result in saturation of the binding site. 
 
Competition binding 
 Competition binding assays can be used to determine the ability of unlabelled compounds to 
compete with binding of a fixed concentration of the labeled ligand (which is set after KD 
determination). Hence, these experiments are used to estimate the affinity of unlabeled ligands for 
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the receptor of interest. Competition curves are obtained by plotting specific binding as a percentage 
of total binding against the log concentration of the competing ligand.  
 
Procedure  
 
Saturation binding 
 hmGluR2-CHO-K1 membranes were thawed and homogenized using the Ultra Turrax 
homogenizer and the protein concentration was measured using the Bradford Bio-Rad Protein Assay 
kit. Membranes were diluted in ice-cold binding buffer containing 50 mM Tris-HCl, pH 7.4, 10 mM 
MgCl2 and 2 mM CaCl2. Table 7 summarizes the different protein amounts, radioligands and their 
concentration as well as the unlabeled competitor ligand (to determine non-specific binding) used 
for the various saturation binding experiments. 
 
Table 7. Protein amount, radioligand and respective concentrations and unlabeled competitor ligand used for the 
saturation binding experiments.  
Radioligand Radioligand concentrations (nM) 
Unlabeled 
competitor ligand 
Protein concentration (μg/assay) 
Stably 
transfected WT 
Transiently 
transfected WT 
and hmGlu2 
mutants 
[
3
H]-LY341495 0.25/0.5/0.75/1/1.25/1.5/2/3/6/9/10 1 mM glutamate 10 20 
[
3
H]JNJ-
46281222 
0.25/0.5/0.75/1/2/3/4/5/7.5/10/15/20 
10 μM                      
JNJ 42341806 75 150 
 
 The reaction mixture contains membrane protein (400 l) and the radioligand (50 l) in a 
total volume of 500 μl. To measure total binding, 50 l of buffer, supplemented with DMSO as a 
control (1% DMSO f.c.) where needed, was added. To measure non-specific binding 50 l of the 
unlabeled competitor ligand was added. The reaction mixture was incubated at room temperature 
(RT) for 60 minutes. To stop the incubation, a filtration step was performed over Whatman Filters in 
the Brandel Harvester system (Biomedical Research and development laboratories, USA). With the 
radioligand [3H]-LY341495 the filters used were GF/B and with the radioligand [3H]JNJ-46281222 
GF/C filters presoaked in 0.1% polyethylenimine (Sigma-Aldrich), for 1h, were used. After filtration, 3 
ml of scintillation fluid was added and shake for 10 minutes. Radioactivity was measure in a Liquid 
Scintillation Analyzer Tri-Carb 2810TR (PerkinElmer), after incubation overnight. 
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Competition Binding 
 Competition binding was only performed with [3H]-LY341495. Similarly as above, the reaction 
mixture contained 10 μg of membrane protein, 3 nM of [3H]-LY341495 and 1 mM of glutamate to 
determine non-specific binding, in a total volume of 500 μl. To assess the affinity of glutamate, 
increasing concentrations were added in order to determine the concentration of glutamate needed 
to inhibit 50% of binding (=IC50). The reaction mixture was incubated for 60 minutes at RT and the 
subsequent filtration step was done using a Unifilter-96 GF/B filter plates in a 96-well PerkinElmer 
filtermate harvester and the plates were dried overnight. The remaining radioactivity was measured 
in a Microplate scintillation and luminescence counter (Packard), after addition of 40 μl of 
Microscint™ O.  
 
2.10. Data Analysis 
Data analysis was performed using GraphPad Prism version 4.02 for Windows (GraphPad 
Software, San Diego, USA). Concentration-response curves were fitted using non-linear regression 
analysis fitting the equation: Y=Bottom + (Top-Bottom)/(1+10^((LogEC50-X)*HillSlope)). Saturation 
binding experiments were analyzed using a non-linear regression analysis.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. Results 
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3.1. Orthosteric binding site integrity 
In a previous study, mGlu2 receptor mutations selected based on sequence alignment and 
homology modeling and docking (see Table 6; Methods section), some of which were already 
described in literature, were tested (Master thesis of Farinha, 2012). After transient transfection with 
the mutated hmGlu2 receptor DNA, the integrity of the orthosteric binding site was validated 
through radioligand and functional binding assays.  . Also for the additional set of mutant receptors, 
that was only applied in this thesis, similar assays were performed to verify that the orthosteric 
binding site was not compromised. 
 
3.1.1. Transfection efficiency 
After DNA purification and confirmation of the sequence of WT and mutant hmGlu2 receptor 
DNA, CHO-K1 cells were transiently transfected. Every time a transfection was performed, enhanced 
green fluorescent protein (EGFP-N1) was also included to evaluate the transfection efficiency. 
Overall, transfection efficiency was in the range of 35-45% (Figure 23).  
 
 
 
 
Figure 23. Visualization of EGFP-N1 expression. Cells were transiently transfected with EGFP-N1 each time that a 
transfection was done, in order to check transfection efficiency. The images represent an example of this evaluation and 
correspond to the transfection of: A: Mutation V736A; B: Mutation V700L; C: Mutation F776A 
3.1.2. Receptor expression and orthosteric ligand binding 
 To verify receptor expression in the membranes of the CHO-K1 cells, Western blots were 
performed using an antibody that recognizes a 47 amino acid sequence of the C-terminal tail of the 
mGlu2 receptor. The controls used were non-transfected CHO-K1 cells (referred to as CHO-K1) and 
CHO-K1 cells either stably or transiently transfected with the WT form of the receptor. Figure 24 
shows, with exception of the non-transfected cells, one immunoreactive band running at ~100 kDa 
corresponds to the monomeric form of the mGlu2 receptor and one band running at ~200 kDa that 
corresponds to the homodimer form. This analysis shows that although the receptor has been 
mutated, it is correctly expressed at the cell membrane.  
A A B C 
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Figure 24. Western blot analysis on mGlu2 WT and mutant receptors to illustrate the expression of the receptors in CHO-
K1 cells after stable (for WT hmGlu2) or transient transfection (for WT and mutant hmGlu2). Mutants are indicated with 
the corresponding mutation number (See Table 6, Methods section). As expected, the mGlu2 monomer (~100 kDa) and 
dimer (~200 kDa) are observed and this staining pattern is the same for WT and mutant mGlu2. Actin (antibody diluted 
1:10000 in TBS-T) is presented as a loading control. Molecular weight markers are indicated in kDa. 
 
To further confirm the receptor expression, as well as the orthosteric binding site integrity in 
the mutated receptors, a set of binding experiments with the orthosteric mGlu2/3 antagonist [3H]-
LY341495 was performed. All the mutants showed the same specific [3H]-LY341495 binding indicating 
that the mutations do not affect the orthosteric pocket binding. Glutamate is also able to displace 
the antagonist which indicates that the mutated receptors are able to bind glutamate in the same 
way as the WT (Figure 25). Moreover, glutamate inhibited binding with a similar pIC50 value (Table 8) 
indicating that the affinity for glutamate does not seem to be altered in the mutated receptors 
compared to the WT receptor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25. Representative graphs of [
3
H]-LY341495 binding, showing the displacement of LY341495 (orthosteric 
antagonist) by glutamate, on WT (transiently and stably transfected) and mutated hmGlu2 receptors expressed in CHO-K1 
cells. Results are presented as mean±SD of one experiment performed in triplicate.  A – Total binding results are expressed in 
dpm (disintegrations per minute); B – Results are presented as percentage of specific binding. Specific binding is calculated 
as: total binding (absence of glutamate) minus non-specific binding which correspond to the binding in the presence of 1 mM 
glutamate. 
LY Binding %
-9 -8 -7 -6 -5 -4 -3 -2
-10
10
30
50
70
90
110
Stable WT
Transient WT
G730I
A733T
A740I
C616S
 
Sigmoidal dose-response (variable slope)
Best-fit values
     BOTTOM
     TOP
     LOGEC50
     HILLSLOPE
     EC50
Stable
-2.537
105.2
-4.875
-0.8966
1.332e-005
WT
-1.914
104.9
-4.671
-1.069
2.134e-005
mutant 34
-2.270
103.7
-4.654
-1.032
2.218e-005
mutant 35
-1.671
107.5
-4.639
-1.160
2.295e-005
mutant 36
-2.210
104.4
-4.600
-0.9417
2.511e-005
mutant 37
0.6509
110.0
-4.729
-1.079
1.868e-005
log [glutamate], M
%
 s
p
e
c
if
ic
 b
in
d
in
g
, 
[3
H
]-
L
Y
3
4
1
4
9
5
B LY Binding
-9 -8 -7 -6 -5 -4 -3 -2
0
500
1000
1500
2000
2500
3000
Stable
WT
G730I (#34)
A733T (#35)
A740I (#36)
C616S (#37)
 
Sigmoidal dose-response (variable s ope)
Best-fit values
     BOTTOM
     TOP
     LOGEC50
     HILLSLOPE
     EC50
Stabl
74.84
2653
-4.878
-0.9052
1.325e-005
WT
88.92
2718
-4.667
-1.053
2.151e-005
Mut nt 34
78.10
1570
-4.657
-1.029
2.201e-005
Mutant 35
76.86
1222
-4.645
-1.153
2.263e-005
Mut t 36
71.80
1866
-4.601
-0.9337
2.507e-005
Mutant 37
89.19
1421
-4.721
-1.065
1.900e-005
log [glutamate], M
[3
H
]-
L
Y
3
4
1
4
9
5
 b
in
d
in
g
A 
66 
 
As can be seen in Figure 25A the absolute binding values are different for every mutation; 
however this is an expected result taking into account that the levels of receptor expression can vary 
between each transient transfection. 
Table 8. Summary of pIC50 values for displacement of [
3
H]-LY341495 binding by glutamate on WT (stable and transiently 
transfected) and mutated hmGlu2 receptors. Data is presented as mean ± SD for WT. For the mutated receptors one 
concentration-response curve was performed in triplicate.  
Receptor region Mutation pIC50 n 
---- Stable WT 4.9 ± 0.09  12 
---- Transient WT 4.7 ± 0.06  13 
TM2 
C616S  4.7 1 
I622F  4.7 1 
TM4 
T641S  4.7 1 
A6742  4.7 1 
A681F  5.2 1 
I693M  4.7 1 
V695S  4.7 1 
A696V  4.7 1 
EL2 
G706R  4.7 1 
E708Y  4.6 1 
A710L  4.7 1 
P711A  4.7 1 
V716T  4.7 1 
T718I  4.7 1 
TM5 
A726S  4.6 1 
G730I  4.7 1 
A733T  4.6 1 
A740I  4.6 1 
TM7 V798A  4.4 1 
 
3.1.1. Glutamate potency 
 Table 9 and Figure 26 show the results for the functional studies using [35S]GTPуS which 
were performed to evaluate the glutamate potency of the WT and hmGlu2 mutated receptors. The 
aim of these experiments was to verify the effect of the mutations on glutamate–mediated receptor 
activation.  The potency of glutamate (pEC50) was obtained from concentration-response curves of 
glutamate in CHO-K1 cells expressing the mutated hmGlu2 receptors and WT, both stably and 
transiently transfected. On the WT receptor, glutamate exerts effects with a pEC50 of about 5.1 (EC50 
values of about 9 μM), and as seen in Table 9 all the mutants present similar potencies. It can be 
seen on Figure 26A that the response obtained for the transient WT and mutated hmGlu2 receptors 
is lower than for the stable WT.  
 
 
67 
 
 
 
 
 
 
 
 
 
 
 
The response amplitude was calculated as a ratio between the response obtained with 1 mM 
glutamate and the response obtained under basal conditions (only using assay buffer), taking the 
basal condition as 100% of the response. The results (Table 9) indicate lower response amplitude for 
the transient transfections (WT and mutated receptors) when compared with the stable line. 
Furthermore, between all the mutated hmGlu2 receptors, mutation V798A shows a rather low 
amplitude response although glutamate pEC50 was unchanged compared to WT.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26. Representative graphs of glutamate-induced [
35
S]GTPуS binding. Results are presented as mean±SD of one 
experiment performed in triplicate.  A – Total binding results are expressed in cpm (counts per minute); B – Results are 
presented as percentage of specific binding (total binding (absence of glutamate) minus non-specific binding which 
correspond to the binding in the presence of 1 mM glutamate). 
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Table 9. Summary of the results obtained for glutamate-induced [
35
S]GTPγS binding to WT (transiently and stably 
transfected) and mutated hmGlu2 receptors transiently transfected in CHO-K1 cells. pEC50 values are presented as 
mean±S.D (for the mutations with n≥2). The response amplitude is defined as the ratio between the response obtained 
with 1 mM glutamate and the response obtained under basal conditions (only using buffer), taking the basal condition as 
100% and is presented, in percentage, as mean±S.D. (for the mutation with n≥2), indicating the glutamate stimulation. The 
concentration-curves were performed in triplicate with increasing glutamate concentrations.  
Receptor 
region 
Mutation pEC50 
Response amplitude 
(%) 
n 
---- Stable WT 5.1 ± 0.07 656% ± 154%  11 
---- Transient WT 5.3 ± 0.07 223% ± 59% 8 
TM2 
C616S  5.4 ± 0.03 185% ± 0 2 
I622F  5.3 205% 1 
TM4 
T641S  5.2 181% 1 
A6742S  5.3 225% 1 
A681F  5.4 237% 1 
I693M  5.3 199% 1 
V695S  5.3 ± 0.09 180% ± 16% 2 
A696V  5.9 ± 0.54 184% ± 26% 2 
EL2 
G706R   5.3 ± 0.07 212% ± 35% 3 
E708Y  5.1 ± 0.02 178% ± 5% 2 
A710L  5.2 ± 0.14 293% ± 58% 2 
P711A 5.4 ± 0.16 214% ± 28% 2 
V716T  5.2 217% 1 
T718I  5.2 176% 1 
TM5 
A726S  5.3 ± 0.01 192% ± 8% 2 
G730I  5.3 ± 0.1 231% ± 19% 3 
A733T  5.2 ± 0.14 174% ± 18% 2 
A740I  5.3 ± 0.13 165% ± 36% 2 
TM7 V798A  5.2 132% 1 
 
3.2. Effect of mutations on PAM’s activity – [35S]GTPуS binding 
3.2.1. Expansion of previous studies: evaluation of additional mutations 
In a previous study, it was observed that mutations F643A, G689V, W773A, S688L/G689V, 
S688L/G689V/N735D and S644A/V700L/H723V had a general impact on the activity of structurally 
distinct mGlu2 PAM compounds (Master thesis of Farinha, 2012). 
Further selections of amino acids, based on mGlu2/3 comparison, were made in order to 
further delineate the molecular interaction of mGlu2 PAMs and verify whether some of these 
additional amino acids contribute to the binding pocket previously hypothesized.  
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In order to evaluate the effect of the different mutations on the activity of the various mGlu2 
PAMs, a functional assay ([35S]GTPуS binding assay) was performed. Since a large number of 
compounds and mutants had to be tested, a preliminary analysis was performed. For that an initial 
screening comparing the mutant and WT receptor was performed, using only two concentrations of 
PAM compounds: one concentration that displays 50% (EC50) of the PAM activity and a concentration 
that produces 100% (EC100) of PAM activity.  These values were previously determined with the use 
of stably transfected cells. The rationale for selecting these concentrations was as follows: while for 
some compound-mutant pairs, there may be an effect on both potency and Emax (example given in 
Figure 27A), for others the compound concentration-response curve may have shifted to the right, 
indicating a lower potency, leaving the Emax (detected with the use of EC100) unchanged compared 
to WT (example in Figure 27B). In the latter example, using just the EC100-equivalent concentration 
would have masked the effect of the mutation. 
 
 
 
 
 
 
 
 
 
 
A set of 14 compounds of different chemical classes (1,4-Pyridone, 1,5-Pyridone, 
Imidazopyridine, Isoquinolone, Triazolopyridine) and 3 reference PAMs (see appendix 2) was tested 
via this screening approach on mutations selected based on mGlu2/3 comparison (Table 6; Methods 
section).  
PAM compounds were tested using 4 μM glutamate (correspondent to the glutamate EC20) 
and for each PAM compound, [35S]GTPуS binding was calculated as a percentage of the response 
obtained with 1 mM glutamate in the absence of a PAM. The stimulation produced by each 
compound on the different mutated receptors was compared against the stimulation produced on 
the WT, and values below 75% of the response obtained on the WT receptor were considered to give 
a meaningful difference. This screening approach was repeated twice and the results are summarized 
Figure 27. A: Graphic representation of the effect of JNJ 46281222 on glutamate-induced [
35
S]GTPуS on WT and one 
mutated hmGlu2 receptor. Mutation F643A affects both potency and Emax; B: Graphic representation of the effect of JNJ 
42073824 on glutamate-induced [
35
S]GTPуS binding on WT and one mutated hmGlu2 receptor. The compound shows a 
lower potency on the triple mutation when compared to the WT (possible to see with low concentrations, as the EC50). 
When observing the maximal effect (EC100) the compound exhibits the same effect on the mutated and on the WT 
receptor, masking the effect that this mutation has on the compound activity.  
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in Table 10, mutations are sorted by receptor region and the compounds are grouped by chemical 
class. As can be seen in Table 3, only a few mutations seem to interfere with the activity of some 
PAMs and in those cases, the PAM’s response is quite close to the cut-off of 75% of the WT receptor. 
Moreover, a small number of differences between the two screenings were detected. Therefore, to 
further evaluate the effect of these mutations on the activity of the PAM compounds, potency (EC50) 
and relative efficacy (Emax) values were measured for three compounds representing three different 
chemical classes, as well as one reference compound on three different mutations and on mGlu2 WT. 
Results are shown, graphically, in Figure 28.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28. Effect of PAMs on glutamate-induced [
35
S]GTPуS binding in CHO-K1 cells expressing WT and mutated hmGlu2 
receptor. 4 μM glutamate (EC20) was added to induce [
35
S]GTPуS binding by the tested PAMs. Results were normalized as 
percentage of the response to 1 mM glutamate. Data is presented as mean±SD of one experiment performed in triplicate.  
A-B: glutamate-induced [
35
S]GTPуS binding in WT (stably and transiently transfected) and mutation G706R (localized in 
ECL2) by one PAM representative of imidazopyridines (A) and one representative of 1,5-pyridones (B); C: glutamate-
induced [
35
S]GTPуS binding in WT (stably and transiently transfected) and mutation P711A (localized in ECL2) by one PAM 
compound representative of the isoquinolone series; D: glutamate-induced [
35
S]GTPуS binding in WT (stably and 
transiently transfected) and mutation A726S (localized in TM5) by one reference PAM (TEMPS) 
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The potency and relative Emax calculated from the concentration-response curves are 
presented in Table 11, as well as the difference in compound potency calculated as a ratio of EC50 
between WT and mutant mGlu2 receptors. 
As shown in Figure 28 and Table 11 these tested mutations did not seem to affect the activity 
of the PAM compounds that were tested. 
 
 
  
Stable WT 
EL2 TM5 
  G706R (#27) P711A (#30) A726S (#33) 
Chemical class JNJ number EC50 Emax EC50 Emax EC50 Emax EC50 Emax EC50 Emax 
TEMPS(LY487379 
 
35814090 188 113 
129 
 
113     
120 
 
126 
Imidazopyridine 
 
41482012 131 98 
152 
 
105 
212 
 
87     
1,5-Pyridone 
 
35814376 716 193 
471 
 
164 
1019 
 
189     
Isoquinolone 39226421 252 155 
86 
 
141   
210 
 
175   
 
3.1.3. Evaluation of binding pocket for novel chemical structures 
To test if the results previously obtained are verified for other structurally different 
compounds, a second set of [35S]GTPуS binding screening was performed with 10 compounds, 
belonging to the chemical classes pyridazine, azetidine, triazolopyridine and 1,4-pyridone (Appendix 
2).  For these compounds, the whole set of 40 mutants was tested. The screening was done once as 
described before and the results are shown in Appendix 3.  
 For the mutants that appeared to affect the PAM’s activity based on the pre-screening 
method, concentration-response curves were generated with representatives (generally the most 
potent) compounds of each chemical class (pyridone, azetidine, pyridazine and triazolopyridine).  
Figure 29-33 display the results obtained for the 5 representative PAMs on some mutations 
localized in a specific receptor region. Potency (EC50) and relative efficacy (Emax) were calculated for 
the tested PAMs on WT mGlu2 and mutant receptors and are shown in Table 12.  
Results of the screening approach and glutamate-induced [35S]GTPуS binding are described 
by receptor region. 
Transmembrane 2 
Mutations localized in this receptor region did not affect PAM’s activity when the compounds 
were tested in [35S]GTPγS  binding screening. Therefore no further analysis was performed with these 
mutations (see Appendix 3). 
 
Table 11. Potency (EC50) and relative Emax of the enhancement of glutamate-induced [
35
S]GTPуS binding by 4 PAMs on 
WT and mutant receptors after transient transfection. Data is presented as EC50 (nM)) and Emax (percentage) of one 
experiment performed in triplicate.  
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Transmembrane 3 
Figure 29 displays the results obtained from the concentration-dependent enhancement of 
glutamate-induced [35S]GTPyS binding on mutations localized in transmembrane 3. Mutation F643A 
elicited the biggest effects (EC50 > 10000 nM) (Figure 29B, C and E) with exception of compound JNJ-
42073824 which shows an increase of the EC50 of about 64-fold (Table 12). For the compounds only 
tested in screening, this mutation also seems to have a large effect (see Appendix 3).  Mutations 
R635A and L639A showed some effect on PAM’s activity when tested through screening approach, 
but when the most potent compounds were tested on concentration-response curves, no alterations 
were observed (Table 12, Figure 29). Mutation R636A reduced the activity of compound JNJ-
42073824 (triazolopyridine), with an increase of the EC50 of 4 fold and mutation S644A produced an 
increase of about 3-fold in the EC50 of compound JNJ-54768636 (pyridone) and for compound JNJ-
54757027 (triazolopyridine) no curve was possible to  generated. Also, through screening analysis, 
this mutation elicit a response lower than 75% of the WT for all the compounds tested. The 
remaining mutations localized in this region (T641S and A642S) did not show any effect when the 
screening was performed.  
 
Transmembrane 4 
 [35S]GTPyS screening showed that some of the mutations localized in TM4 elicit effect on 
PAM’s activity with exception of mutations S688L, A681F, I693M, V695S and A696V, and thus these 
particular mutations were not further tested. For the compounds tested in concentration-response 
curves the triple mutation N735D/G689V/S688L showed the most prominent results, causing a 
decrease in potency and in Emax (20-fold increased in EC50) for compound JNJ-54768636 (Table 12) 
and for the other compounds tested elicited values of EC50 > 10000 nM (Table 12, Figure 30A-C,E). 
The other triple mutation S644A/V700L/H723V and mutation G689V/S688L caused a similar effect, 
decreasing potency and Emax for almost every compound tested with exception of the 
representative of the chemical class azetidine (Figure 30, Table 12).  Mutation V700L shows an 
increase of 3-fold on the EC50 of compound JNJ-54757027, while for the other compounds this 
mutation does not elicit any effect. In the case of mutation G689V no effect was observed on the 
azetidine or pyridazine series, as exemplified with JNJ- 54800681 and JNJ-54445001, while for the 
other classes an increase of 3 to 7 in EC50 was observed.  
 
Extracellular loop 2 
 The preliminary analysis showed that mutations localized in the EL2 did not influence PAM’s 
activity with exception of mutation H723. However when tested in concentration-dependent 
enhancement of glutamate-induced [35S] GTPγS binding, this mutation only showed a decrease on 
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potency of compound JNJ-54768636 (4-fold increase on EC50), while Emax was not affected (Figure 
31, Table 12). 
 Although mutation V716T showed some effect on screening, this could not be confirmed 
after further analysis (Figure 31, Table 12). 
 
Transmembrane 5 
 In this receptor region, mutation M728A, S731A, L732A and N735D decreased compound’s 
activity when these were tested with 2 concentrations (screening approach).  This could, however, 
not be confirmed for mutation M728A when was tested in glutamate-induced [35S] GTPуS binding. 
On the other hand, mutation N735D showed dramatic effects, eliciting values of EC50 > 10000 nM 
(Figure 32A and C, Table 12). When the concentration-response curve was possible to generate, this 
mutation elicited a decrease in potency, with an increase of the EC50 of 14 fold (Table 12). Although 
mutation S731 showed an increase of 4 and 5-fold on EC50 for compound JNJ-54445001 and JNJ-
42073824, respectively, for compound JNJ 54800681, this mutation did not affect potency but a 
decrease on Emax was observed. Mutation L732A elicits an effect so large on the activity of 
compound JNJ 54757027 given values of EC50 > 10000 nM. Mutations D725A, A733T and A740I did 
not show any effect when tested in screening while for V723A, A726S and G730I a slight decrease in 
the compound’s activity was observed.  
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Figure 29. Effect of PAMs on glutamate-induced [
35
S]GTPуS binding in WT mGlu2 and mGlu2 with mutations located in 
transmembrane 3 (TM3). Concentration-dependent enhancement of 4 μM glutamate-induced [
35
S]GTPуS binding by 5 
PAMs, representative of 4 chemical classes.  Results are expressed as a percentage of the response to 1 mM glutamate, 
and refer to one experiment performed in triplicate. 
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Figure 30. Effect of PAMs on glutamate-induced [
35
S]GTPуS binding in WT mGlu2 and mGlu2 with mutations located in 
transmembrane 4 (TM4). Concentration-dependent enhancement of 4 μM glutamate-induced [
35
S]GTPуS binding by 5 
PAMs, representative of 4 chemical classes.  Results are expressed as a percentage of the response to 1 mM glutamate, 
and refer to one experiment performed in triplicate. 
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Figure 31. Effect of PAMs on glutamate-induced [
35
S]GTPуS binding in WT mGlu2 and mGlu2 with mutations located in 
extracellular loop 2 (EL2). Concentration-dependent enhancement of 4 μM glutamate-induced [
35
S]GTPуS binding by 5 
PAMs, representative of 4 chemical classes.  Results are expressed as a percentage of the response to 1 mM glutamate, 
and refer to one experiment performed in triplicate. 
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Figure 32. Effect of PAMs on glutamate-induced [
35
S]GTPуS binding in WT mGlu2 and mGlu2 with mutations located in 
transmembrane 5 (TM5). Concentration-dependent enhancement of 4 μM glutamate-induced [
35
S]GTPуS binding by 5 
PAMs, representative of 4 chemical classes.  Results are expressed as a percentage of the response to 1 mM glutamate, and 
refer to one experiment performed in triplicate. 
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Transmembrane 6 
Mutation W773A affects the activity of all compounds tested, disrupting completely their 
ability to generate a concentration-response curve (Figure 33). Mutation F776A showed a small 
effect in two compounds when tested on screening but mutation F780A did not affect PAM’s activity. 
 
Transmembrane 7 
The only mutation of this receptor region was not tested in concentration-response curves 
because of the fact that this mutation presents rather low response amplitude (see Table 9) even 
though some effect was seen in screening (Table 12).  
   
In the cases that just a small effect was observed when mutations were analyzed by 
screening with two concentrations it was considered as not having an effect.  
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Figure 33. Effect of PAMs on glutamate-induced [
35
S]GTPуS binding in WT mGlu2 and mGlu2 with mutations located in 
transmembrane 6 (TM5). Concentration-dependent enhancement of 4 μM glutamate-induced [
35
S]GTPуS binding by 4 PAMs, 
representative of 3 chemical classes.  Results are expressed as a percentage of the response to 1 mM glutamate, and refer to 
one experiment performed in triplicate. 
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3.2. Radioligand binding assays 
After assessing the impact of the mutated amino acids on efficacy, through use of a 
functional assay ([35S] GTPуS binding) it is important to verify the impact on binding of the compound 
(affinity). For that reason, binding assays were done to assure that the compound is able to bind to 
the receptor. For these experiments, a tritiated form of a PAM compound ([3H] JNJ-46281222) was 
used and the mutations chosen were N735S, S688L/G689V, S688L/G689V/N735D, F643A, 
S644A/V700L/H723V, M728A and V736A. 
To make sure that potential differences observed in the binding levels are due to alterations 
in binding affinity rather than differences in receptor densities, it was first important to use 
membrane pools with similar receptor densities.  For this, we used the orthosteric antagonist [3H]-
LY341495. 
3.2.1. Choosing the optimal protein amount 
[3H]LY341495 binding experiments were done with diverse concentrations of WT (stable and 
transiently transfected) hmGlu2 receptors with the aim of knowing the optimal range of protein 
amount that should be used in further binding experiments. Figure 34 shows that the specific binding 
of 3 nM [3H] LY341495 was proportional to the amount of membrane protein and increased linearly 
between 2.5 and 30 μg of membrane protein/assay.  
 
 
  
For the stably transfected CHO-K1 cells the use of 10 μg of protein/assay was taken as 
optimal for experiments with this radioligand. To have equivalent protein amounts, 20 μg of 
protein/assay was chosen for transiently transfected WT.  This amount was also chosen for mutant 
forms of the mGlu2 receptor that were transiently expressed in CHO-K1 cells. 
 
Figure 34.  Specific [
3
H] LY341495 binding is linear with amount of membrane protein in Stable WT (left) and in Transient 
WT (right). Increased concentrations of these pools were tested, namely, 2.5, 5, 7.5, 10, 12.5, 15, 20 and 30 µg/assay. Data 
is presented as mean of triplicate determinations from one experiment.  
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3.2.2. Determination of receptor density 
After determining which protein amount to use, saturation binding experiments using [3H]-
LY341495 were done with the main aim of knowing the density (Bmax) of mGlu2 receptors expressed 
in cell membranes of WT (stable and transiently transfected) and mutated receptors. The results can 
be seen in Figure 35.  
As seen in Table 13 the Bmax is quite similar for every mutated receptor with exception for 
mutation L639A. For that reason this mutation was not chosen for further analysis. 
 
Table 13. Summary of receptor density (BmaX) and of the equilibrium dissociation constants (KD) of [
3
H]-LY341495 binding 
to WT (stably and transiently transfected) and mutant hmGlu2 receptors; Experiments were done once, in triplicate, with 
exception for both WT (n=2) 
 
KD (nM) Bmax (fmol/mg of protein) 
mGlu2 Stable WT 1.51 ± 0.41 15898 ± 619 
mGlu2 Transient WT 1.31 ± 0.27 6673 ± 838 
S688L/G689V (#4) 0.97 9060 
S688L/G689V/N735D (#5) 1.2 6633 
L639A (#7) 1.35 1775 
F780A (#13) 1.23 4128 
M728A (#19) 1.07 8408 
V736A (#21) 1.25 6393 
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Figure  35. Saturation binding curves (on the left) and their correspondent scatchard plots (on the right) of [
3
H]-LY341495 
binding to WT (transiently and stably transfected) and some of the mutated hmGlu2 receptors. Mutation L639A belongs 
to TM3 of the receptor, S688L/G689V and S688L/G689V/N735D are part of the TM4, M728A and V736A part of TM5 and 
F780A belongs to TM6. Data is presented as nanomolar specifically bound. Data points were determined in triplicate (n=1).   
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3.2.3. Effect of mutations on PAM’s affinity – [3H]PAM binding 
Further saturations experiments were done with [3H]-JNJ 46281222, which is a PAM of the 
triazolopyridine chemical class, with final concentrations of 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 7.5, 10, 15 
and 20 nM. Since previous work determined the use of 75 μg/assay for the stable WT as optimal 
(data not shown), this protein amount was chosen for the stable WT, while – in analogy with the 
higher amounts needed for [3H] LY341495 binding, 150μg/assay was used for the transiently 
transfected pools. Also, looking at the Bmax results obtained in section 3.1.1., one can see that 
receptor expression for transient transfections seems more or less half of the stable transfection.  
Firstly, the mutants not affecting JNJ-46281222 activity on [35S] GTPуS binding were 
evaluated for [3H]-JNJ 46281222 saturation binding and as can be seen in Figure 36, the selected 
mutants M728A and V736A are able to bind this PAM compound confirming the lack of effect on the 
glutamate-induced [35S] GTPγS binding.  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 36. Saturation binding curves and correspondent Scatchard plots of [
3
H]-JNJ 46281222 binding to WT 
(stably and transiently transfected) and mutant mGlu2 receptors (M728A and V736A) expressed in CHO-K1 
membranes.  75 μg/assay for stable WT and 150 μg/assay for transient WT and mutated hmGlu2 receptors were 
used. Data are presented as nanomolar specifically bound. Data points were determined in triplicate (n=1).  
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It is important to note, however, that the saturation binding experiments shows for the 
stable WT a specific binding (calculated with 4 nM of radioligand) of 30%, while transient WT showed 
23% of specific binding and for mutation M728A and V736A the percentage was only 22% and 6% 
respectively. Because of this low specific binding it was not possible to calculate the KD.  Therefore 
one concentration of this radioligand, equivalent to the KD (4nM) previously determined on stable 
mGlu2 WT cells (data not shown),  was chosen and further experiments were performed. In this case, 
additionally to the mutations already tested in [3H]-JNJ 46281222 saturation binding, mutations 
N735S, S688L/G689V, S688L/G689V/N735D, F643A and S644A/V700L/H723V were included, to verify 
whether binding of PAMs was affected. Figure 37 shows that mutations S644A/V700L/H723V, 
M728A and V736A are still able to bind the PAM compound as demonstrated before. As for the other 
mutations (N735D, S688L/G689V, S688L/G689V/N735D and F643A) the binding was disrupted. Figure 
37B shows a clear effect for the triple mutation (S688L/G689V/N735D) which totally prevented the 
binding of the PAM to the receptor, as well as for mutation N735D. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 37. Effect of mutated mGlu2 receptors on [3H]JNJ 46281222 (PAM) binding (4 nM). Data is presented as 
mean ± SD of two independent experiments performed in triplicated (exception for mutation N735D, F643A, 
S644A/G689V/N735D, S644A/V700L/H723V; n=1). A: Results are presented as DPM; TB – Total binding (only used 
buffer), BL – Blank (non-specific binding), determined with addition on 10 μM JNJ-42341806 (mGlu2 PAM). B: Results 
are presented as percentage of specific binding.   
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 The experiment was also done in the presence of 1 mM glutamate. Interestingly, the addition 
of the agonist increased the binding in both stable and transient WT. The specific binding of the 
stable WT is 55% in the absence of glutamate against 80% with 1 mM glutamate. For the transient 
WT the values are 25% against 55% without and with glutamate, respectively. For the mutated 
receptors the binding also increased with addition of glutamate. However mutations N735D, 
S688L/G689V/N735D, F643A and S644A/V700L/H723V still show reduced specific binding compared 
to WT (Figure 38B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 38. Effect of mutated mGlu2 receptors on [
3
H]JNJ 46281222 (PAM) binding. 4nM of Radioligand were incubated 
with 1 mM glutamate. Data is presented as mean ± SD of two independent experiments performed in triplicated 
(exception for mutation N735D, F643A, S644A/G689V/N735D; n=1). A: Results are presented as DPM; TB – Total binding 
(only used buffer), BL – Blank (non-specific binding), determined with addition on 10 μM JNJ-42341806 (mGlu2 PAM). B: 
Results are presented as percentage of specific binding.   
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4. Discussion
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To overcome the disadvantages associated to the use of orthosteric ligands as therapeutic 
approaches, alternative approaches are being looked into. One of these alternatives is the use of 
allosteric modulators. As already mentioned, targeting mGlu2 with PAMs may improve selectivity, 
tractability and tolerability. Thus, the emerging field of positive allosteric modulation of mGlu2 offers 
exciting potential for novel therapeutics in neurological and psychiatric disorders (Trabanco et al. 
2011).   
The presence of different modulatory sites on mGlu2 and mGlu3 receptors allows for the 
development of compounds that selectively potentiate mGlu2 but not mGlu3 or vice versa. 
Therefore it is important to investigate the molecular factors involved in the interaction between 
PAM compounds and the receptor. In this way it is possible to understand how these compounds 
bind and activate the receptor and may help the development of sub-type selective compounds. 
In the present study, the molecular interaction of 24 PAMs with the mGlu2 receptor was 
clarified. In order to asses these interactions, the activity and affinity of these compounds on WT and 
point-mutated mGlu2 receptors was compared, aiming the confirmation or identification of new 
amino acids important for the interaction between PAMs and the mGlu2 receptor.  
The ultimate goal of these studies is to generate a putative binding pocket for mGlu2 PAMs, 
which may help future chemistry efforts to identify druggable mGlu2 PAMs. 
4.1. Expression of WT and mutated mGlu2 receptors 
The Western Blot analysis revealed that the WT and mutated forms of the mGlu2 receptor 
were expressed and that the levels of expression are variable between the forms transiently 
transfected, while in the case of CHO-K1 cells stably transfected with WT receptor exhibit higher 
levels of expression. 
4.2. Comparison between the affinity and potency for glutamate between WT and 
mutated hmGlu2 receptors 
Besides the confirmation that mGlu2 receptors are being expressed by CHO-K1 cells it is also 
important to know if the receptor is still able to bind glutamate (orthosteric agonist) to know if the 
mutations do not have an effect on the receptor conformation that is needed to bind glutamate. It 
was possible to observe that glutamate was able to displace [3H]-LY341495 in a concentration-
dependent manner. The pIC50 values obtained were similar between the WT and tested mutated 
hmGlu2 receptors, which indicate that the mutated receptors are expressing the receptor and are 
able to bind glutamate in a similar way as the WT receptor.  
To evaluate functional proprieties of the mutated receptors, concentration-response curves 
for glutamate-induced [35S] GTPуS binding were generated. With this assay it was possible to 
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compare the functional activity of the WT and mutated receptors. Results showed that the response 
amplitude was variable within the mutated receptors, which is likely due to differences in receptor 
expression or transfection efficiency. Nevertheless all mutated receptors elicited concentration-
response curves with similar potencies as the WT receptor (stably and transiently transfected), 
indicating that the mutated receptors were functional active and that mutations did not affect 
glutamate potency towards the receptor.  
These results were expected since mutations were introduced outside of the extracellular 
domain; therefore no changes in the affinity or potency of orthosteric ligand were expected to be 
observed when compared to the WT. 
4.3. Effect of mutations on positive allosteric modulators activity 
Schaffhauser et al. (2003) identified amino acids present in TM4 and TM5 (S688, G689 and 
N735) as critical for the binding of LY487379. Studies with other compounds confirm that these 
amino acids seem to form a binding pocket (Hemstapat et al. 2007; B. A. Rowe et al. 2008). A recent 
study performed at Janssen Pharmaceutica showed that in addition to those already mentioned, 
amino acids present in TM3, 5 and 6 are also important for receptor-PAM interaction. These 
additional residues were: F643, W773, R635, L639, H723, L732, and F776. 
The present study greatly expands this study both in terms of testing additional chemical 
classes as well as in further delineating the mGlu PAM binding pocket via the evaluation of additional 
compound-amino acid interactions.  The results confirm the information about the critical amino 
acids for PAM’s activity. In addition, it was shown that residues localized in TM2, not tested 
previously, do not affect the PAM’s activity, and therefore do not contribute to the mGlu2 binding 
pocket.  
Overall, effects of mutations F643A, S644A, G689V, G689V/S688L, S644A/V700L/H723V, 
H723V, S731A, L732A, N735D and W773A were similar across all the different compounds tested. 
This was especially surprising for the novel azetidine series as the compounds within this class did 
not seem to overlay in an mGlu2 PAM pharmacophore model that was generated previously. 
Interestingly, the mutations that showed to be important for the activity of these compounds were 
already reported as critical for the formation of the binding pocket: F643A, N735D/G689V/S688L, 
N735D ad W773A.  
Overall, this study shows that structurally different mGlu2 PAMs appear to share a common 
group of amino acids to which they bind. 
It is important to note that some amino acids reported for Lundstrom et al. (2011) as 
important for NAM’s activity also have an effect on PAM’s activity (F643A, H723V, L732A and 
W773A), indicating an overlap in the binding site on mGlu2 receptor for PAMs and NAMs. However, 
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mutation F780A shown a large effect on the binding of the NAMs Ro 4988546 and Ro 5488608, but 
no effect was observed on the activity of the tested PAMs. On the other hand, mutation S644A and 
S688L/G689V did not affect NAM’s activity (Lundström et al. 2011) but was observed a big effect on 
PAM’s activity, especially regarding the double mutation.  
 Allosteric binding studies have been performed for other mGlu receptors. Residue P655 on 
mGlu5 was shown  to be important for the binding of a mGlu5 receptor NAM (MPEP) (Pagano et al. 
2000) and the residue V757 on mGlu1 receptor was shown to be crucial for the binding of PAM 
compounds. In this study it was shown that the correspondent residues on mGlu2, F643 and L732, 
have a large effect on the tested PAMs.  
 
 
 
 
 
 
 
 
mGlu2/3 comparison 
Analysis of differences between mGlu2 and mGlu3 is important since these differences are 
what give compound selectivity.  
In a previous study it was observed that the amino acids S644, V700 and H723 form an 
important binding pocket for the activity of PAMs and are responsible for their subtype-specificity 
(Master Thesis of Farinha, 2012). The results obtained in this study, when different compounds were 
tested, confirm this information. As shown, the triple mutation (S644A/V700L/H723V) caused the 
major effects, though the activity of compounds of the chemical class azetidine was not affected by 
this mutation. Furthermore, the other mutations selected based on sequence comparison between 
the mGlu2 and mGlu3 receptor (Table 6; Methods Section) do not affect the binding of any PAM 
compounds. These data give additional information about the critical amino acids for the subtype 
specificity highlighting the importance of the ones previously mentioned (S644, V700 and H723).    
Amino acids indentified in literature that were also selected based on this criteria, namely, 
Ser688, Gly689 and Asn735 (B. A. Rowe et al. 2008; Hemstapat et al. 2007), were also tested in this 
Figure 39. 3D representation of the receptor and the mutations that seem to affect the binding of the tested PAMs 
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study and in the previous one.  Once again the results obtained in this study confirm the ones 
previously obtained. In both studies was observed that mutation S688L did not affect PAM’s activity. 
However mutation G689V, N735D and the double and triple mutation of these three amino acids had 
a high impact on the activity of all PAMs tested, with exception for the chemical class azetidine. In 
this case just the triple mutation and N735D had an effect when tested on glutamate-induced 
[35S]GTPуS binding (EC50 > 10000 nM), which confirms the already reported importance of this amino 
acids in mGlu2 receptor subtype specificity.   
4.4. Effect of mutations on positive allosteric modulators affinity 
Saturation binding experiments with [3H] JNJ-46281222 confirm it can still bind to the 
mutants at which it do not exerts a functional effect. Since the specific binding is reduced in the 
transient transfected pools it was impossible to calculate the KD. Therefore it may be useful to do 
saturation bindings with addition of the agonist (glutamate). 
The use of this tritiated form of PAM with one concentration confirm, that the mutations 
M7287A and V736A (previously tested in [3H] JNJ-46281222 saturation binding), are still able to bind 
this compound in a similar way as the WT. Thus it is confirmed that the lack of effect on [35S]GTPyS 
binding assay is due to the fact that these mutations do not elicit any change in the physical PAM-
receptor interaction. On the other hand, this experiment shows in fact, that mutations that elicit a 
substantial decrease in the potency of JNJ-46281222 when tested in glutamate-induced [35S]GTPyS 
binding  (mutations N735D, S688L/G689V/N735D and F643A) are not able to bind the tritiated 
version of this compound in the same way as the WT. The triple mutation did abolish the binding 
ability when no glutamate was added.   These data suggest that the activity of the PAM is reduced 
due to a lower binding affinity. This was confirmed when testing binding in the presence of 
glutamate, which was shown to increase binding at the WT receptor. Mutation S644A/V700L/H723V 
showed a reduction in the specific binding when glutamate is present, however this effect was not as 
big as seen for the mutations N735D, S688L/G689V/N735D and F643A.  Nevertheless it is important 
to note that this mutation elicits a larger increase of EC50 of 13, when tested in the functional assay, 
and the other ones show an increase of 56 to 135-fold. Therefore these results confirm the data 
obtained when glutamate-induced [35S]GTPyS assay was performed, with exception of mutation 
S688L/G689V. In the presence of glutamate the double mutation showed the same specific binding 
levels as the WT; however it was expected to have a similar binding pattern as mutation 
S644A/V700L/H723V. In general, these results seem to be in accordance with the data obtained from 
the functional assay. Nevertheless this was just a modest set of experiments and further 
investigation with other tritiated PAMs and mutants should be performed. 
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Conclusion Remarks 
This study showed that the impact of several mutations is consistent between structurally 
different molecules indicating that mGlu2 PAMs may share a common group of amino acids to which 
they bind. Nevertheless is important to note that an apparent overlap in the binding site for NAMs 
and PAMs exists. It was also demonstrated that additional amino acids that were selected based on 
mGlu2/3 comparison did not seem to be important for PAM activity. Moreover it is suggested that 
the activity of the tested PAMs is reduced due to lower binding affinity.  
The knowledge obtained from this study help gives further insight in the receptor regions 
involved in the formation of the binding pocket for allosteric modulators, contributing to the 
development of novel, potentially improved mGlu2 PAMs. 
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Appendix 1. Complete names of the compounds mentioned in the text  
Abbreviation Name 
(1S, 3R) - ACPD 1S, 3R-1-aminocyclopentane-1,3,4-tricarboxylic acid 
(1S, 3S) - ACPD 1S, 3S-1-aminocyclopentane-1,3-dicarboxylic acid 
(2R, 4R) - APDC (2R, 4R)-4-Aminopyrrolidine-2,4-dicarboxylic acid 
(2S, 4S) - ADPD 2S, 4S-2-amino-4-(4,4-diphenylbut-1-yl)-pentane-1,5-dioic acid 
4C3HPG RS-4-carboxy-3-hydroxyphenylglycine 
BAY36-7620 (3aS6aS)-6a-naphtalen-2-ylmethyl-5-methyliden-hexahydro-cyclopental[c]furan-1-on  
BINA 3’[[(2-Cyclopentyl-2,3-dihydro-6,7-dimethyl-1-oxo-1H-inden-5-yl)oxy]methyl]-1[1,1’-
biphenyl]-4-carboxylic acid 
CPCCOEt 7-hydroxyiminocyclopropan[b]chromen-1ª-carboxylic acid ethyl ester 
CTZ Cyclothiazide  
DCG-IV (2S,2’R,3’R)-2-(2’,3’)-Dicarboxycyclopropyl glycine 
EM-TBPC 1-ethyl-2-methyl-6-oxo-4-(1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)-1,6-dihydro-
pyrimidine-5-carbonitrile  
LCCG-1 (2S,1’S,2’S)-2-(carboxycyclopropyl)glycine 
LY341495 2SS-2-amino-2-(1S,2S-2-carboxycyclopropan-1-yl)-3-(xanth-9-yl)proprionic acid 
LY354740 (1S,2S,5R,6S)-(+)-2-aminobicylco[3.1.0]hexane-2,6-dicarboxylic acid 
LY379268 (-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylic acid 
LY404039 (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid 
LY487379 N-[4-(2-methoxyphenoxy)phenyl]-N-(2,2,2-Trifluoroethylsulfonyl)-pyrid-3-
ylmethylamine 
MCCG-I α-methyl-L-CCG-I 
MGS0028 (1R,2S,5S,6S)-2-amino-6-fluoro-4-oxobicyclo[3.1.0]hexane-2,6-dicarboxylic acid 
MGS0039 (1R,2R,3R,5R,6R)-2-amino-3-(3,a-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-
2,6-dicarboxylic acid 
MK-801 Dizocilpine 
MNI-135 [3-(7-iodo-4-oxo-4,5-dihydro-3H-benzo[1,4]diazepin-2-yl)-benzonitrile] 
MNI-136 [7-bromo-4-(3-pyridin-3-yl-phenyl)-1,3-dihydro-benzo[1,4]diazepin-2-one] 
MNI-137 [4-(7-bromo-4-oxo-4,5-dihydro-3H-benzo[1,4]diazepin-2-yl)-pyridine-2-carbonitrile] 
MPEP 2-methyl-6-(phenylethynyl)pyridine 
MPPG α-methyl-4-phosphonophenylglycine 
MRLSD-650 2-[(6,7-dichloro-2-cyclopentyl-2-methyl-1-oxo-2,3-dihydro-1H-inden-5-yl) oxy]-N-[4-
(1H-tetraazol-5-yl) phenyl] acetamide 
MSPG α-methyl-4-sulfonophenylglycine 
MTPG Α-methyl-4-tetra-zoylphenylglycine 
PCCG-IV (2S, 1’S, 2’S, 3’R)-2-(2’-carboxy-3’-phenylcyclopropyl) glycine 
Ro 01-6128 (Diphenylacetyl)-carbamic acid ethy ester  
Ro 67-4853 (9H-Xanthen-9-ylcarbonyl)-carbamic acid butyl ester  
Ro 67-7476 (2S)-2-(4-Fluorophenyl)-1-[(4-methylphenyl)sulfonyl]-pyrrolidine  
RO4988546 5-[7-trifluoromethyl-5- (4 - trifluoromethyl-phenyl)-pyrazolo[1,5-a]pyrimidin-3-
ylethynyl]-pyridine-3-sulphonic acid  
RO5488608 3′ -(8-methyl-4-oxo-7- trifluoromethyl -4,5-dihydro-3H-benzo[b][1,4]diazepin-2-yl)-
biphenyl-3-sulphonic acid  
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Appendix 2. Chemical class and name of each positive allosteric modulator tested in this study  
 
Chemical class Compound 
1,4-Pyridone 
JNJ-40068782 
JNJ-41329782 
JNJ- 54768636 
JNJ- 54768597 
JNJ-54752997 
1,5-Pyridone JNJ-35814376 
Azetidine 
JNJ-54352272 
JNJ-54750592 
JNJ-54469805 
JNJ-54800681 
Imidazopyridine JNJ-41482012 
Isoquinolone 
JNJ-39226421 
JNJ-40297036 
Pyridazine JNJ-54445001 
Triazolopyridine 
JNJ-46281222 
JNJ-46356479 
JNJ-42153605 
JNJ-42329001 
JNJ-43245046 
JNJ-42073824 
JNJ-54757027 
THIIC (LY2607540) JNJ-52149617 
BINA JNJ-35815013 
TEMPS (LY487379) JNJ-35814090 
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